US20080311182A1 - Multistage delivery of active agents - Google Patents
Multistage delivery of active agents Download PDFInfo
- Publication number
- US20080311182A1 US20080311182A1 US11/836,004 US83600407A US2008311182A1 US 20080311182 A1 US20080311182 A1 US 20080311182A1 US 83600407 A US83600407 A US 83600407A US 2008311182 A1 US2008311182 A1 US 2008311182A1
- Authority
- US
- United States
- Prior art keywords
- stage
- particle
- particles
- stage particle
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 64
- 239000002245 particle Substances 0.000 claims abstract description 695
- 238000000034 method Methods 0.000 claims abstract description 96
- 239000002105 nanoparticle Substances 0.000 claims abstract description 87
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 230000004888 barrier function Effects 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 46
- 239000011859 microparticle Substances 0.000 claims abstract description 45
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 28
- 239000012216 imaging agent Substances 0.000 claims abstract description 19
- 239000011148 porous material Substances 0.000 claims description 130
- 210000004027 cell Anatomy 0.000 claims description 120
- 238000011068 loading method Methods 0.000 claims description 118
- 229910052710 silicon Inorganic materials 0.000 claims description 76
- 239000010703 silicon Substances 0.000 claims description 76
- 239000002502 liposome Substances 0.000 claims description 52
- 239000000463 material Substances 0.000 claims description 35
- 230000008685 targeting Effects 0.000 claims description 35
- 229920000642 polymer Polymers 0.000 claims description 33
- 239000000126 substance Substances 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 210000005166 vasculature Anatomy 0.000 claims description 24
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000007783 nanoporous material Substances 0.000 claims description 13
- 230000008384 membrane barrier Effects 0.000 claims description 12
- 210000000865 mononuclear phagocyte system Anatomy 0.000 claims description 12
- 239000003961 penetration enhancing agent Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000000633 nuclear envelope Anatomy 0.000 claims description 9
- 230000008497 endothelial barrier function Effects 0.000 claims description 8
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 230000008499 blood brain barrier function Effects 0.000 claims description 7
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 7
- 239000002041 carbon nanotube Substances 0.000 claims description 7
- 229910021393 carbon nanotube Inorganic materials 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 239000000919 ceramic Substances 0.000 claims description 7
- 229910003472 fullerene Inorganic materials 0.000 claims description 7
- 230000003204 osmotic effect Effects 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 238000009792 diffusion process Methods 0.000 claims description 6
- 230000007515 enzymatic degradation Effects 0.000 claims description 6
- 239000000693 micelle Substances 0.000 claims description 6
- 238000000518 rheometry Methods 0.000 claims description 6
- 239000004065 semiconductor Substances 0.000 claims description 6
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 5
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 5
- 210000002469 basement membrane Anatomy 0.000 claims description 5
- 229920000831 ionic polymer Polymers 0.000 claims description 5
- 239000002082 metal nanoparticle Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 230000003021 clonogenic effect Effects 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 210000004940 nucleus Anatomy 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 229910010293 ceramic material Inorganic materials 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 238000004137 mechanical activation Methods 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 3
- 239000000560 biocompatible material Substances 0.000 claims 1
- 229910052809 inorganic oxide Inorganic materials 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 239000011856 silicon-based particle Substances 0.000 description 141
- 239000002109 single walled nanotube Substances 0.000 description 94
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 73
- 239000000243 solution Substances 0.000 description 65
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 62
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 48
- 239000007983 Tris buffer Substances 0.000 description 46
- 229920001223 polyethylene glycol Polymers 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- -1 APTES modified silicon Chemical class 0.000 description 37
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 37
- 229910021426 porous silicon Inorganic materials 0.000 description 35
- 239000003981 vehicle Substances 0.000 description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 31
- 239000002096 quantum dot Substances 0.000 description 26
- 229910001868 water Inorganic materials 0.000 description 26
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 24
- 238000011534 incubation Methods 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 18
- 238000006731 degradation reaction Methods 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 230000004807 localization Effects 0.000 description 16
- 230000007935 neutral effect Effects 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 14
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000004626 scanning electron microscopy Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000006143 cell culture medium Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 229960004679 doxorubicin Drugs 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 239000010931 gold Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000942 confocal micrograph Methods 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 239000005543 nano-size silicon particle Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 210000001578 tight junction Anatomy 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 238000002723 toxicity assay Methods 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- 108010092160 Dactinomycin Proteins 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229910052814 silicon oxide Inorganic materials 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 238000004630 atomic force microscopy Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229960000640 dactinomycin Drugs 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000012632 fluorescent imaging Methods 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 239000002078 nanoshell Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 241000252506 Characiformes Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 231100000416 LDH assay Toxicity 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000000339 bright-field microscopy Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- 238000012874 electrostatic modification Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000005530 etching Methods 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- 229960001101 ifosfamide Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000012342 propidium iodide staining Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 239000004054 semiconductor nanocrystal Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 102100033824 A-kinase anchor protein 12 Human genes 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000013128 Endothelin B Receptor Human genes 0.000 description 2
- 108010090557 Endothelin B Receptor Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000779382 Homo sapiens A-kinase anchor protein 12 Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000011166 aliquoting Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 230000004890 epithelial barrier function Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 2
- 229960004783 fotemustine Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000000981 high-pressure carbon monoxide method Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001459 lithography Methods 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 238000004518 low pressure chemical vapour deposition Methods 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 239000002070 nanowire Substances 0.000 description 2
- 150000004767 nitrides Chemical class 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 238000001637 plasma atomic emission spectroscopy Methods 0.000 description 2
- 238000001020 plasma etching Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000002444 silanisation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-O trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=[NH+]C(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-O 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 229940053867 xeloda Drugs 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- FUOJEDZPVVDXHI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-azido-2-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1C(=O)ON1C(=O)CCC1=O FUOJEDZPVVDXHI-UHFFFAOYSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QJGDGUBLGKFNDB-UHFFFAOYSA-N 1-azido-2-nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC=C1N=[N+]=[N-] QJGDGUBLGKFNDB-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- XUNWNJDKCHSGOA-UHFFFAOYSA-N 2-dodecoxyethyl(trimethyl)azanium Chemical compound CCCCCCCCCCCCOCC[N+](C)(C)C XUNWNJDKCHSGOA-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- BRONALLIAIBEPV-UHFFFAOYSA-N 4-(2-hydroxyethyl)isoindole-1,3-dione Chemical compound OCCC1=CC=CC2=C1C(=O)NC2=O BRONALLIAIBEPV-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- OVIMLFTXXVUDPD-UHFFFAOYSA-N C(CCCCCCCCCCCCC)(=O)C(O)(C[N+](C)(C)C)CC([O-])=O.C(CCCCCCCCCCC)C(O)(C[N+](C)(C)C)CC([O-])=O.C(CCCCCCCCC)C(O)(C[N+](C)(C)C)CC([O-])=O Chemical compound C(CCCCCCCCCCCCC)(=O)C(O)(C[N+](C)(C)C)CC([O-])=O.C(CCCCCCCCCCC)C(O)(C[N+](C)(C)C)CC([O-])=O.C(CCCCCCCCC)C(O)(C[N+](C)(C)C)CC([O-])=O OVIMLFTXXVUDPD-UHFFFAOYSA-N 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010042645 PZ-peptide Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000001015 X-ray lithography Methods 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- XULVYJHOSWAWHO-UHFFFAOYSA-N [Ca].C(CCCCCCCCCCCCCCC)(=O)NCC(=O)O.C(CCCCCCCCCCC)NC(C1=CC=CC=C1)C(=O)O Chemical compound [Ca].C(CCCCCCCCCCCCCCC)(=O)NCC(=O)O.C(CCCCCCCCCCC)NC(C1=CC=CC=C1)C(=O)O XULVYJHOSWAWHO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000002048 anodisation reaction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229940009025 chenodeoxycholate Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000276 deep-ultraviolet lithography Methods 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001473 dynamic force microscopy Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000000609 electron-beam lithography Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- ODYPFMHOOQOHEF-UHFFFAOYSA-N hexadecanoylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC[N+](C)(C)C ODYPFMHOOQOHEF-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 239000002101 nanobubble Substances 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 238000000696 nitrogen adsorption--desorption isotherm Methods 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BHTRKEVKTKCXOH-BJLOMENOSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-BJLOMENOSA-N 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-M taurocholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-M 0.000 description 1
- WBWWGRHZICKQGZ-FREJXKSPSA-N tauroursocholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-FREJXKSPSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- QTBKGUJGLJSBID-UHFFFAOYSA-K trisodium decanoate dodecanoate octanoate Chemical compound [Na+].[Na+].[Na+].CCCCCCCC([O-])=O.CCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O QTBKGUJGLJSBID-UHFFFAOYSA-K 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
Definitions
- the present inventions relate generally to the field of nanotechnology and, in particular, to compositions utilizing micro and/or nanoparticles for delivery active agents, such as therapeutic and imaging agents, and methods of making and methods of using such compositions.
- an active agent such as a therapeutic or imaging agent
- an active agent should travel through vasculature, reach the intended target at full concentration, then act selectively on diseased cells and tissues only, without creating undesired side effects.
- a therapeutic or imaging agent should travel through vasculature, reach the intended target at full concentration, then act selectively on diseased cells and tissues only, without creating undesired side effects.
- Nano-scale and micro-scale drug delivery systems are promising candidates for providing solutions to the problem of optimizing therapeutic index for a treatment, i.e. maximizing efficacy, while reducing health-adverse side effects.
- Even modest amounts of progress towards this goal have historically engendered substantial benefits across multiple fields of medicine, with the translatability from, for example, a subfield of oncology to a field as distant as the treatment of infectious disease being granted by the fact that the progresses had a single common denominator in the underlying technological platform.
- liposomes the first nanovector therapy to reach health-care fruition over 10 years ago for treatment of Kaposi's sarcoma, have also yielded advances in the treatment of breast and ovarian cancers, as well as fungal infections.
- nanovector platforms include polymer-based platforms, dendrimers, gold nano-shells, semiconductor nano-crystals, fullerenes, biologically derived nano-constructs, silicon- and silica-based nanosystems and superparamagnetic nanoparticulates are described in the literature 49-75 .
- composition which comprises at least one first stage particle that is a micro or nanoparticle and that has (i) a body, (ii) at least one surface, and (iii) at least one reservoir inside the body, such that the reservoir contains at least one second stage particle that comprises at least one active agent.
- a method comprising administering to a subject a composition comprising: at least one first stage particle, that is a micro or nanoparticle and that has (i) a body, (ii) at least one surface and (iii) at least one reservoir inside the body, such that the reservoir contains at least one second stage particle that comprises at least one active agent.
- a method of making a multistage delivery system comprises (A) providing at least one first stage particle, that is a micro or nanoparticle and that has (i) a body, (ii) at least one surface (iii) at least one reservoir inside the body; (B) providing at least one second stage particle and (C) loading the at least one second stage particle inside the reservoir of the first stage particle.
- FIG. 1 illustrates a multistage delivery vehicle, in accordance with an embodiment of the invention.
- the first stage particle contains inside second stage particles.
- the second stage particles may comprise at least one active agent, such as a therapeutic agent or an imaging agent.
- the first stage particle also contains inside an additional agent, such as a permeation enhancer or an additional active agent, which may be an imaging agent or a therapeutic agent.
- the second stage particles contain third stage particles.
- FIG. 2 illustrates the principle of operation of a multistage delivery vehicle administered intravascularly, in accordance with an embodiment.
- the first stage particle localizes at the targeted vasculature location. Upon the localization, the particle releases permeation enhancers that generate a fenestration in the vasculature.
- Second stage particles carry targeting moieties, such as antibodies. The second stage particles may permeate through the fenestration and target specific cells, that carry surface marker antigens, using the antibodies.
- FIG. 3 Panel A, depicts time dependence of amino and carboxy modified quantum dots (q-dots) in APTES modified “large pore” LP and “small pore” nanoporous silicon first stage particle.
- FIG. 3 Panel B, demonstrates an effect of second stage PEG-FITC-SWNT nanoparticles concentration on their loading into nanoporous silicon first stage particles.
- Y-axis reads mean fluorescence.
- FIG. 4 Panels A-D, demonstrate time dynamics of second stage nanoparticles loading into nanoporous silicon first stage particles.
- Panel A for “large pore” (LP) oxidized silicon first stage particles
- Panel B for LP APTES modified silicon first stage particles
- Panel C for “small pore” (SP) oxidized silicon first stage particle
- Panel D for SP APTES modifies silicon first stage particles.
- Y-axis reads mean fluorescence.
- FIG. 5 demonstrates time dynamics of second stage nanoparticles release from LP oxidized nanoporous silicon first stage particles (Panel A) and LP APTES modified nanoporous silicon first stage particles (Panel B).
- Y-axis reads released payload (%).
- FIG. 6A Panel A, presents the concentration effect of loading carboxy modified quantum dots and FITC-conjugated single wall carbon nanotubes (SWNTs). Y axis in Panel A reads mean fluorescence (%). FIG. 6A , Panel B, demonstrates fluorescence quenching of Fluorescein Isothiocyanate (FITC) conjugated Single Wall Carbon Nanotubes (SWNT).
- FITC Fluorescein Isothiocyanate
- FIG. 6B relates to optimization of chemical condition for loading of second stage particles into nanoporous silicon particles.
- Nanoporous silicon particles were mixed with second stage nanoparticles (Q-dots in FIG. 6B , Panel C and Panel D; PEG-FITC-SWNTs in Panel E and Panel F) in the presence of increasing concentration of TRIS.
- High concentration of TRIS helped in increasing the amount of Q-dots loaded into the first stage silicon particles (Panel C and Panel D).
- loading efficiency of PEG-FITC-SWNTs reached its peak at 20 Mm TRIS and then decreased at higher TRIS concentrations, Panel E and Panel F.
- Y axis in Panels B-F reads mean fluorescence.
- FIG. 7 demonstrates data for loading and release respectively FITC conjugated with SWNT second stage particles into LP nanoporous silicon first stage particles.
- Panel A presents load columns, corresponding to the amount of FITC-SWNT initially loaded in the nanoporous silicon first stage particles after exposure to a FITC-SWNT solution prior to washing. Wash columns in Panel A corresponds to the amount of FITC-SWNT after washing the first stage particles.
- the actual load of the FITC-SWNT in the first stage particles is the amount of FITC-SWNT retained in the first stage particles after washing, i.e., a difference between the respective values in the load column and in the wash column.
- Panel B shows data for release of FITC-SWNT from the first stage particles over time.
- the total amount of FITC-SWNT released from the first stage particles over time i.e., a sum of all the columns in Panel B, substantially matches the difference between respective load and wash columns in Panel A.
- Y axis in Panels A and B reads amount of FITC-SWNTs (ng).
- FIGS. 8A-B present data for lipid based second stage particles loading into nanoporous silicon first stage particles.
- Panels A-C show data for cationic and neutral liposomes loaded into 1 micron nanoporous silicon first stage particles.
- Panel A shows confocal microscopy images of neutral liposomes (left) and cationic liposomes (right).
- Panels B and C present respectively FACS analysis and Excel quantification of neutral and cationic liposome loading into 1 micron nanoporous silicon first stage particles.
- Y axis in Panel B reads particle number and Y axis in Panel C reads green fluorescence (logarithmic values).
- FIG. 8A Panels A-C show data for cationic and neutral liposomes loaded into 1 micron nanoporous silicon first stage particles.
- Panel A shows confocal microscopy images of neutral liposomes (left) and cationic liposomes (right).
- Panels B and C present respectively FACS analysis and Excel quant
- Panel D shows time dynamics of loading liposomes containing Alexa 555 labeled SiRNA into 3.5 micron nanoporous oxidized silicon first stage particles.
- Y axis in Panel D reads mean fluorescence.
- Panel E and Panel F present fluorescent microscopy images visualizing fluorescence associated with liposomes containing Alexa 555 labeled SiRNA into 3.5 micron nanoporous silicon first stage particles.
- FIG. 9 Panels A-D, demonstrate Scanning Electron Microscopy (SEM) images of “large pore” (LP) nanoporous silicon first stage particles.
- FIG. 10 Panels A-D, demonstrate Scanning Electron Microscopy (SEM) images of “small pore” (SP) nanoporous silicon first stage particles.
- FIG. 11 Panels A-D, demonstrate degradation of nanoporous silicon particles measured using Z2 Coulter® Particle Counter.
- Y axis in Panels A and B reads number of particles.
- Y axis in Panels C and D reads volume of particles.
- FIGS. 12A-B demonstrate degradation of nanoporous silicon particles measured using Inductive Coupled Plasma—Atomic Emission Spectrometry.
- FIG. 12A Panel A, for LP oxidized silicon particles; Panel B for SP oxidized silicon particles; FIG. 12B , Panel C, for LP APTES modified silicon particles.
- Panel D for SP APTES modified silicon particles.
- Y axis in FIGS. 12A-12B reads concentration of silicon (ng/mL).
- FIG. 13 demonstrates biocompatability of nanoporous silicon first stage particles by presenting bright field microscopy images of selected nanoporous silicon particles and Human Umbelical Vein Endothelial Cells (HUVEC) cells.
- Panel A demonstrates images for small pore oxidized silicon nanoparticles
- Panel B demonstrates images for small pore APTES modified silicon nanoparticles
- Panel C demonstrates images for large pore oxidized silicon nanoparticles
- Panel D demonstrates images for large pore APTES modified silicon nanoparticles.
- first image day 0 (2 hrs after particles addition), second image day 1; third image day 2; fourth image day 3.
- FIGS. 14A-B demonstrate biocompatibility of nanoporous silicon particles by presenting data for Lactate Dehydrogenase (LDH) toxicity assay on HUVEC cells incubated with nanoporous silicon nanoparticles.
- LDH Lactate Dehydrogenase
- FIGS. 15A-B present data for MTT proliferation assay on HUVEC cells incubated with nanoporous silicon nanoparticles.
- Y axis in FIG. 15A , Panels A-B and FIG. 15B , Panels C-F reads absorbance at 570 nm.
- FIG. 16 Panels A-C, present FACS 3D Profiles of HUVEC cells incubated with Nanoporous Silicon Particles and analyzed for their size and shape.
- FIG. 17A-17D present FACS 3D Profiles of HUVEC cells incubated with Nanoporous Silicon First Stage Particles and stained with propidium iodide to study cell cycle.
- FIGS. 18A-C present statistical analysis of different phases of the cell cycle of cells exposed to nanoporous silicon first stage particles.
- Y axis in FIG. 18A , Panels A-C, FIG. 18B , Panels D-G, and FIG. 18C , Panels H-K reads % of total cell population.
- FIG. 19 Panels a and b, demonstrate SEM images of a porous silicon particle.
- the size and shape of the LP and SP particles are the same, the size and structure of the pores are significantly different.
- FIG. 20 presents results of flow cytometric and fluorescence microscopy analysis of loading of fluorescently labeled Q-dots and PEG-FITC-SWNTs into nanoporous silicon particles.
- An increase in the amount of nanoparticles in the loading solution resulted in an increase in the mean fluorescence of silicon particles ( ⁇ LP APTES+Carboxyl Q-dots ⁇ LP oxidized+Amino Q-dots ⁇ SP APTES+Carboxyl Q-dots ⁇ SP oxidized+Amino Q-dots) measured by flow cytometry (Panels A and B).
- Fluorescent microscopy (Panels C and D) confirmed that the fluorescence associated to first stage particle was dimmer when the amount of nanoparticles used was lower.
- Y axis in Panels A and B reads mean fluorescence.
- FIG. 21 presents time dependent loading and releasing of second stage particles in nanoporous silicon first stage particles.
- LP oxidized (Panel a) LP APTES (Panel b)
- SP oxidized (Panel c) SP APTES (Panel d)
- second stage nanoparticles ⁇ Carboxyl q-dots, ⁇ Amino q-dots, ⁇ PEG-FITC-SWNTs
- Histograms in Panels e-h represent a percentage of second stage particles released from the first stage silicon particles with the passage of time.
- FIG. 22 presents confocal microscopy images demonstrating concentrated loading of Q-dots in a highly porous region of the back side of silicon particle.
- Panel a shows confocal microscopy images reconstructed in a series of 3 dimensional projections showing a single porous silicon particle rotated to display different vantage points.
- Panel b shows computer generated 3 dimensional models illustrating the rotation of the particle as shown in Panel a.
- FIGS. 23A-23C illustrate simultaneous loading and releasing of Q-dots and PEG-FITC-SWNTs second stage particles in nanoporous silicon first stage particles.
- Flow cytometry analysis showing background green and red fluorescence of LP APTES particles (Unloaded; FIG. 23A , Panel A and Panel B respectively) and the shifts of the fluorescence signals after the incubation with PEG-FITC-SWNTs (+SWNTs), Q-dots (+Q-dots) and both (+Q-dots+SWNTs).
- Flow cytometry analysis show that PEG-FITC-SWNTs load rapidly and stabilize, while Q-dots gradually load before reaching a plateau, see FIG. 23B , Panel C.
- FIG. 23 B Panel D.
- Confocal microscopy images show the localization of the Q-dots (red) and PEG-FITC-SWNTs (green) in a single porous silicon particle.
- FIG. 23C Panel E, Panel F and Panel G show bright field, green and red fluorescence respectively, while Panel h shows overlay of the 3 channels are shown. Yellow display showed co-localization of green and red fluorescent signals.
- Y axis in FIG. 23 B, Panel D reads mean fluorescence; Y axis in Panel D reads released payload.
- FIG. 24 Panels a-m, show fluorescent spectroscopy images related to incubating nanoporous silicon particles loaded with second stage particles with HUVEC cells for 1 h at 37 C.
- the second stage particles are Q-dots; in Panels e-h, the second stage particles are PEG-FITC-SWNTs; in Panels j-m, the second stage particles are Q-dots and PEG-FITC-SWNTs.
- FIG. 24 Panels d, h and m are bright field images showing the details of particle morphology.
- FIG. 25 Panels A-C, present computer models representing the three major physical, chemical and electrostatic mechanisms responsible for loading and release of second stage nanoparticles in first stage silicon carrier.
- Size Dependency The size of the pores determines the type of nanoparticles that are preferably loaded into the silicon particle.
- Dose Dependency A larger number of nanoparticles in the loading solution cause an increase in the number of particles that are loaded into the pores.
- Charge Dependency Compatibly charged nanoparticles will be attracted into the pores, whereas incompatible charges will partially repel the nanoparticles and thus prevent them to enter the pores.
- FIG. 26 Panels A-B, present data for liposomes containing SiRNA loaded into nanoporous silicon first stage particles.
- Panel A Alexa 555 fluorescently labeled siRNAs were encapsulated into nano-liposomes and loaded into the 1st stage nano-vectors. The data show that the fluorescence associated with the porous Silicon carrier increased with the amount of nanoliposomes.
- Y axis reads mean fluorescence in Panel A.
- FIG. 26 , Panel B presents a graph showing relative amount of liposomes released from first stage nanoporous silicon particles. Y axis reads % of total amount of released liposomes.
- the assembled multistage particles were incubated with 10% fetal bovine serum (pH 7.4) and release of nanoliposomes from 1st stage particles was followed along time using fluorimetry. Complete unloading was achieved in about 36 h.
- FIG. 27 demonstrates optimization of physical condition for loading of quantum dots and PEG-FITC-SWNTs.
- Y axis in Panel a and Panel b reads mean fluorescence.
- Porous silicon particles were desiccated in a desiccator over night and then mixed with the loading solution containing the second stage nanoparticles. Loading efficiency in dry condition was not significantly different than loading efficiency in a wet environment (p value>0.5).
- Biochemical environment of the target body site refers to one or more intrinsic physiological conditions at the target site, such as pH, salt conditions, temperature, or the presence of target specific moieties, effective to initiate and promote release of the particle content.
- Biodegradable refers to a material that may dissolve or degrade in a physiological medium or a biocompatible polymeric material that may be degraded under physiological conditions by physiological enzymes and/or chemical conditions.
- “Mucoadhesive” refers to the capability of the particle to adhere to the mucosal layer, which lines the entire surface in the small and large intestine. Adherence is mediated by ligands grafted to the surface of the particles, which bind to chemical receptors present in mucin or the surface of the intestinal epithelial cells.
- Targeting moiety is any factor that may facilitate targeting of a specific site by a particle.
- the targeting moiety may be a chemical targeting moiety, a physical targeting moiety, a geometrical targeting moiety or a combination thereof.
- the chemical targeting moiety may be a chemical group or molecule on a surface of the particle; the physical targeting moiety may be a specific physical property of the particle, such as a surface such or hydrophobicity; the geometrical targeting moiety includes a size and a shape of the particle.
- Microparticle means a particle having a maximum characteristic size from 1 micron to 1000 microns, or from 1 micron to 100 microns. “Nanoparticle” means a particle having a maximum characteristic size of less than 1 micron.
- Biocompatible refers to a material that, when exposed to living cells, will support an appropriate cellular activity of the cells without causing an undesirable effect in the cells such as a change in a living cycle of the cells; a change in a proliferation rate of the cells and a cytotoxic effect.
- a composition that includes two or more stages of particles, such that particles of a later stage (smaller size particles) are contained in particles of an earlier stage (larger particles), will potentially provide one or more advantages for treating, preventing and/imaging a physiological condition, such as a disease, in a subject, which may be any animal with a blood system (e.g., the subject may be a warm blooded animal, such as mammal including human being).
- a physiological condition such as a disease
- a subject which may be any animal with a blood system (e.g., the subject may be a warm blooded animal, such as mammal including human being).
- an active agent such as a therapeutic agent or an imaging agent, is preferentially delivered and/or localized to a particular target site in a body of a subject.
- Preferential delivery and/or localization means that an amount or concentration of the active agent delivered to and/or localized at the target site is higher than an amount or concentration of the active agent delivered to and/or localized at other sites in the body of the subject; (2) a multistage composition sequentially overcomes multiple biological barriers in a body of the subject; and (3) a multistage composition allows for simultaneous delivery and localization at the same or different target site of multiple active agents.
- an active agent such as a therapeutic or imaging agent, formulated conventionally or in a nanovector, encounters a multiplicity of biological barriers that adversely impact the agent's ability to reach an intended target at a desired concentration.
- the biological barrier may be, for example, an epithelial or endothelial barrier, such as a blood-brain barrier or intestinal lumen endothelium, that are based on tight junctions, that prevent or limit para-cellular transport of an active agent.
- Each of the endo/epithelial barrier includes a plurality of sequential subbarriers, such as tight junction barriers, that owe their molecular discrimination to one or more zonula occluden proteins, and one or more additional biological membranes, such as vascular endothelial basement membrane or a musocal layer of the intestinal endothelium.
- Cells of the reticulo-endothelial system may also act as a biological barrier against an active agent encapsulated inside nanoparticles, as such cells sequester/uptake the nanoparticles.
- the biological barrier may be also represented by a cell membrane or a nuclear membrane in a cell that an active agent has to come through.
- a delivery vehicle that, in embodiments, acts in multiple stages.
- Each stage of the vehicle is defined by a particle having a separate intended function, which may be different from an intended function of a particle of another stage.
- a particle of one stage is designed to target a specific body site, which may be different from a site targeted by a particle of another stage, and thus to overcome or bypass a specific biological barrier, which is different from a biological barrier being overcome or bypassed by a particle of another stage.
- a particle of each subsequent stage is contained inside a particle of an immediately preceding stage.
- a particle of any particular stage may contain an active agent, such as a therapeutic agent or an imaging agent, intended for use at this particular stage.
- a particle of the last stage is an active agent formulated as a nanoparticle or alternatively the last stage particle contains the active agent inside, while a particle of any earlier stage per se may or may not comprise an active agent.
- a particle of each stage in addition to targeting a specific body site, is designed in such a way that it is capable to perform targeted release of its content.
- the number and type of stages in the multistage delivery vehicle depends on several parameters, including administration route and an intended final target for the active agent. An embodiment of a multistage delivery vehicle is illustrated on FIG. 1 .
- the particle of the first stage is a micro or nanoparticle.
- the first stage particle has a characteristic size of at least 500 microns or at least 1 mm.
- Such a particle may be configured to contain inside at least one micro or nanoparticle, which in turn may contain inside at least one particle of a smaller size.
- the first stage particle is any particle that is capable of containing inside particles of a smaller size.
- the first stage particle is a top-down fabricated particle, i.e., a particle prepared by top-down microfabrication or nanofabrication methods, such as photolithography, electron beam lithography, X-ray lithography, deep UV lithography or nanoprint lithography.
- top-down fabrication methods such as photolithography, electron beam lithography, X-ray lithography, deep UV lithography or nanoprint lithography.
- the particle of the first stage may be configured to overcome at least one of the following biological barriers: a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
- biological barriers a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
- the first stage particle may have a body that is defined by a size and a shape of the particle and one or more reservoirs inside the body.
- One or more second stage particles may be contained inside the reservoir.
- the body of the first stage particle comprises any appropriate material.
- the material of the body of the first stage particle is biocompatible.
- the body of the first stage particle comprises an oxide material such as silicon oxide, aluminum oxide, titanium oxide, or iron oxide; a semiconductor material, such as silicon; a polymer or a polymer oxide material; or a ceramic material.
- the body of the first stage particle comprises a biodegradable material, such as, for example, nanoporous silicon.
- the biodegradable material may be such that it degrades when exposed to a physiological medium such as silicic acid.
- a material of the body of the first stage particle is substantially the same in different regions of the body.
- the shape of the first stage particle may depend on the administration route. For example, the shape may be configured to maximize the contact between the first stage particle and a surface of the target site, such as endothelium surface for intravascular administration or intestinal epithelium for oral administration. Accordingly, for oral and intravascular administration, the first stage particle may have a selected non-spherical shape configured to maximize the contact between the particle and endothelium surface. Examples of appropriate shapes include, but are not limited to, an oblate spheroid or a disc. For pulmonary administration, i.e., administration to lungs of the subject, the first stage particles may also have a selected non-spherical shape configured to maximize a contact between the particle and one of the epithelial tissues in lungs.
- the first stage particle may also have a spicular shape, which may facilitate entering of the particle from the lungs into a body tissue, not necessarily through the blood circulation.
- a maximum characteristic size of the particle e.g., a diameter for a disc-shaped particle
- a radius of the smallest capillary In humans, such a radius is about 4 or 5 microns. Accordingly, the maximum characteristic size of the particle are, in some embodiments, less than about 3 microns, less than about 2 microns or less than about 1 micron.
- the maximum characteristic size of the first stage particle is from 500 nm to 3 microns, or from 700 nm to 2 microns. Yet in some embodiments for intravascular administration in oncological applications, the maximum characteristic size of the first stage particle is such that the first stage particle could localize at the targeted vasculature site without penetrating a fenestration in vascular cancer endothelium. For such applications, the maximum characteristic size of the first stage particle is greater than about 100 nm, or greater than about 150 nm, or greater than about 200 nm.
- the size of the first stage particle is such so that the particle may penetrate the fenestration. Accordingly, the maximum characteristic size in such applications is preferably less than about 200 nm, or less than about 150 nm, or less than about 200 nm. In some embodiments, one may select a size of the first stage particle that is selected to be a critical radius of normal non-fenestrated vasculature for targeting fenestrated vasculature as detailed in PCT patent application No. PCT/US2006/038916 “Methods and Compositions for Targeting Fenestrated Vasculature” filed Sep. 27, 2006 to Paolo Decuzzi and Mauro Ferrari.
- the first stage particle For oral administration, it may be preferable to use the first stage particle that has a maximum characteristic size greater than about 2 microns or greater than about 5 microns or greater than about 10 microns.
- One advantage of using the first stage particle of such size for oral administration is that such particle may be too large to be endocytosed by intestinal epithelial cells.
- the endocytosis by intestinal epithelial cells has at least two potential disadvantages: 1) the content of the first stage particle may be deactivated as it is processed by the endothelial cell before it reaches the desired target; 2) the potential toxicity of particular carrier, e.g. of the material of the particle, is of greater concern if it is endocytosed than if it is cleared through the gastrointestinal tract.
- the first stage particle has a size ranging from 500 microns to several centimeters, or from 1 mm to 2 cm.
- the maximum characteristic size of the first stage particle is preferably less than about 20 microns but greater than about 5 microns, if a targeted site is located in the lungs' air passages.
- the maximum characteristic site may be less than about 5 microns.
- a characteristic size of the first stage particle is from 50 microns to 1 mm; or from 100 microns to 1 mm.
- One of the functions of the first stage particle is localization at a particular target site.
- target site may be a particular vasculature site.
- the targeted vasculature site may be a tumor vasculature, such as angiogenesis vasculature, coopted vasculature or renormalized vasculature.
- the localization of the first stage particle at the targeted site may be facilitated by geometrical factors, such as the size and the shape of the particle.
- the localization at the targeted site may be also facilitated by one or more recognition factors on the surface of the first stage particle.
- the recognition factor may be a chemical targeting moiety, such as a dendrimer, an antibody, an aptamer, which may be a thioaptamer, a ligand or a biomolecule that binds a particular receptor on the targeted site.
- the chemical moiety may comprise one or more mucoadhesive ligands, as described in Table 1 of U.S. Pat. No. 6,355,270.
- the selectivity of the targeting may be tuned by changing chemical moieties of the surface of the particles.
- coopted vasculature is specifically targetted using antibodies to angiopoietin 2; angiogenic vasculature is recognized using antibodies to vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGFb) or endothelial markers such as ⁇ v ⁇ 3 integrins, while renormalized vasculature are recognized using carcinoembionic antigen-related vell adhesion molecule 1 (CEACAM1), endothelin-B receptor (ET-B), vascular endothelial growth factor inhibitors gravin/AKAP12, a scallofldoing protein for protein kinase A and protein kinase C, see, e.g., Robert S. Korbel “Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?”, Science 26 May 2006, vol 312, no. 5777, 1171-1175.
- the binding between the first stage particle and the molecular marker of the targeted vasculature site should be sufficiently strong to overcome the drag force exerted by the flowing blood.
- This objective may be satisfied by having a relatively large planar surface area for specific binding and a relatively low profile in a capillary's blood flow space, i.e., by having the particle of the selected non-spherical shape, such as an oblate spheroid or a disc.
- the recognition factor may be also a physical recognition moiety, such as a surface charge.
- the charge may be introduced during the fabrication of the particle by using a chemical treatment such as a specific wash. For example, immersion of porous silica or oxidized silicon surface into water may lead to an acquisition of a negative charge on the surface, see, e.g., Behrens and Grier, J. Chem. Phys. 115(14), (2001). P. 6716-6761.
- the surface charge may be also provided by an additional layer or by chemical chains, such as polymer chains, on the surface of the particle.
- polyethylene glycol chains may be a source of a negative charge on the surface. Polyethylene glycol chains may be coated or covalently coupled to the surface as described in P. K.
- the positive charge is introduced, for example, by coating the surface with a basic polymer, such as polylysine or by covalently linking to the surface an amino containing molecule, such as 3-aminopropyltriethoxysilane.
- modeling methods are applied for selecting geometrical factors, such as a size and a shape, and/or surface modification, such as chemical modification and electrostatic modification, of the particle based on one or more properties of the selected target site.
- geometrical factors such as a size and a shape, and/or surface modification, such as chemical modification and electrostatic modification, of the particle based on one or more properties of the selected target site.
- Such modeling methods are disclosed, for example, in 1) U.S. Provisional Patent Application No. 60/829,075 “Particles for Cell Targeting” filed Oct. 11, 2006 to Paolo Decuzzi and Mauro Ferrari; 2) U.S. Provisional Patent Application No. 60/891,584 “Endocytotic particle” filed Feb. 26, 2007 to Paolo Decuzzi and Mauro Ferrari; 3) Decuzzi, P., Causa, F., Ferrari, M. & Netti, P. A.
- the first stage particle is configured to release the second stage particles from its reservoir at the target site.
- the release of the second stage particles may be performed according to a variety of mechanisms, including, but not limited to, diffusion of the second stage particles through the channels connecting the reservoir and the surface of the first stage particle and degradation or erosion of the body the first stage particle.
- the first stage particle is configured to have a characteristic release time longer than a characteristic delivery time of the first stage particle to its target site when administered to the subject.
- the first stage particle is configured to perform a release of the second stage particles from its reservoir that is sustained over a period of time longer than a characteristic delivery time of the first stage particle to its target site when administered to the subject. In some embodiments, the first stage particle is configured to release the second stage particles over a time period longer than at least 0.5 hr; or longer than at least 1 hr; or longer than at least 2 hr; or longer than at least 8 hr; or longer than at least 15 hr; or longer than 30 hr.
- physical localization and/or targeted release of the first stage particle is initiated by one or more intrinsic physiological conditions at the target site such as pH, salt concentrations or temperature.
- physical localization and/or targeted release of the first stage particle is initiated by exogenous stimulation.
- exogenous stimulations include mechanical activation, such activation by ultrasound; electromagnetic activation, such an activation by visible, ultraviolet, near-infrared or infrared light, radiofrequency or X-ray radiation; magnetic radiation.
- the first stage particle may comprise a smart polymer, i.e., a polymer that contracts or expand in a response to a specific stimulus, such as light, temperature or pH.
- the first stage particle may utilize multiple, i.e., more than one recognition/localization/targeting factors, which preferably do not interfere with each other.
- the first particle may have the selected non-spherical shape as discussed above and at the same time carry tumor-targeting antibodies on its surface.
- the surface of the first stage particle may be coated with polymer chains partially or completely.
- the polymer chains may be added after the fabrication of the intravascular stage particle.
- the polymer chains may be hydrophilic chains, such as polyethylene glycol (PEG) chains or synthetic glycocalix chains, which may be used for overcoming the uptake of the particle by cell of the reticulo-endothelial system and, thus, extending the blood circulation of the intravascular stage particle.
- the hydrophilic groups may also serve for enhancement of solubility of the multistage delivery devices.
- a variety of materials may be derivatized with polymer chains.
- polymer chains may be attached by linking carboxylic groups of the polymer and amine or hydroxyl groups in the polymer chains; if the particle's surface material comprises metal such as gold, the polymer chains may be attached to the surface via thiol chemistry; when the particle's surface material comprises an oxide, such silicon oxide, titanium oxide or aluminum oxide, the polymer chains may be attached using silane chemistry.
- the reservoir of the first stage particle may contain one or more additional agents.
- additional agent may include an additional active agent, such as a therapeutic agent or an imaging agent, a targeting agent, one or more penetration enhancers or any combination thereof.
- the penetration enhancer may include one or more compounds listed in Table 1.
- the penetration enhancers may include a basement membrane penetration enhancer that may act against the basement membrane, and/or one or more penetration enhancers, that may act against tight junction proteins (TJPs).
- TJPs tight junction proteins
- An example of the basement membrane penetration enhancer is metalloproteinase, such as Collagenase IV, MMP-2, and MMP-9.
- An example of the anti-TJP penetration enhancer is zonula occluden toxin.
- Anti-TJP penetration enhancers and strategies for modulating tight junction permeability are detailed, for example, in Gonzalez-Mariscal, L., Nava, P. and Hernandez, S. J. Membr. Biol., 2005. 207(2): p. 55-68.
- FIGS. 2A-B illustrate the action of penetration enhancer upon localization of the first stage particle at the targeted vasculature site, in accordance with an embodiment.
- the first stage particle releases the permeation enhancers that generate in the targeted vasculature one or more fenestrations, through which the second stage particles penetrate into the vasculature.
- the first stage particle has one or more channels fluidically connecting the reservoir with the surface, that may be in contact with endo or epithelial cells.
- such first stage particle may be a micro or nano fabricated particle, such as those detailed in U.S. Patent Application Publication No 2003/0114366 and U.S. Pat. No. 6,107,102, and for oral administration, such first stage particle may be a micro or fabricated particle, such as the ones disclosed in U.S. Pat. No. 6,355,270.
- the reservoir and the channels are pores in the body of first stage particle.
- the first stage particle may comprise a porous or nanoporous material.
- the pores of the porous or nanoporous material may be controlled to achieve a desired load of the next stage particles and a desired release rate.
- the nanoporous material with controllable pore size may be an oxide material, such as silicon oxide, aluminum oxide, titanium oxide, or iron oxide. Fabrication of nanoporous oxide particles, also known as sol gel particles, is detailed, for example, in Paik J. A. et. al. J. Mater. Res., Vol. 17, August 2002.
- the nanoporous material with controllable pore size may be also nanoporous silicon.
- Control of pore density, size, shape and/or orientation may be accomplished by changing electrical current and etching time during formation of nanoporous silicon from non-porous silicon. Control of pore density, size, shape and/or orientation may be also accomplished by varying doping in non-porous silicon used for formation of nanoporous silicon. Thus, pore size, density, size, shape and/or orientation of nanoporous may be configured for efficient loading of the second stage particles.
- pore size in nanoporous first stage particles may be, for example, from about 1 nm to about 200 nm; or from about 2 nm to about 100 nm. In some cases, pore size in nanoporous first stage particle may be from about 3 to about 10 nm or from about 5 to about 7 nm. Yet in some cases, pore size in nanoporous first stage particle may be from about 10 to about 60 nm, or from about 20 to about 40 nm.
- to facilitate loading of the second stage particles into pores of the porous or nanoporous material may be modified chemically and/or electrostatically to make it compatible with chemical and/or electrostatical surface properties of the second stage particles.
- the positive charge may be achieved, for example, by depositing on pore surface an amino-containing molecule, such as 3-aminopropyltriethoxysilane.
- For loading positively charged second stage particles it may be preferable to use negatively charged pore surface.
- the negative pore surface charge may be accomplished, for example, by oxidizing pore surface with water.
- the first stage particle has no channels at all.
- Such particle may comprise, for example, a biodegradable material.
- the material may be designed to erode in the GI tract.
- the first stage particle may be formed of metals, such as iron, titanium, gold, silver, platinum, copper, and alloys and oxides thereof.
- the biodegradable material may be also a biodegradable polymer, such as polyorthoesters, polyanhydrides, polyamides, polyalkylcyanoacrylates, polyphosphazenes, and polyesters. Exemplary biodegradable polymers are described, for example, in U.S. Pat. Nos. 4,933,185, 4,888,176, and 5,010,167.
- biodegradable polymer materials include poly(lactic acid), polyglycolic acid, polycaprolactone, polyhydroxybutyrate, poly(N-palmitoyl-trans-4-hydroxy-L-proline ester) and poly(DTH carbonate).
- the body of the first stage particle includes two or more regions configured to contain different populations of second stage particles.
- the body of the first stage particle may have a first region configured to contain a first population of second stage particles and a second region configured to contain a second population of second stage particles.
- the first stage particle formed of porous nanoporous material may be such that its body has two or more porous regions that differ from each other.
- the body of the nanoporous first stage particle may include a first porous region and second porous region that differ from each other in at least one property such as a pore density, pore geometry; pore charge, pore surface chemistry, pore orientation or any combination thereof.
- Such first and second regions may be configured respectively to contain a first and a second population of second stage particles.
- the first and second populations of second stage particles differ in at least one property such as size; shape; surface chemical modification; surface charge or a combination thereof.
- the first and second populations of second stage particles contain the same active agent. Yet, in some embodiments, the first and second population of second stage particles contain respectively a first active agent and a second active agent that are different from each other.
- the first and second populations of second stage particles may be configured to perform different functions.
- the first and second populations may be configured to target respectively a first and second target sites that are different from each other.
- the first population are configured to target a particular site in a body of the subject, while the second population is configured to free circulate in the blood system of the subject.
- the first and the second population target the same target site in a body of the subject but perform a different function at the body site.
- the first population contains a therapeutic agent to be delivered to the target site
- the second population contains an imaging agent to be delivered to the target site for imaging or visualizing the target site.
- the first and the second regions of the body of the first stage particle may be such that at least one of them is a biodegradable region.
- both the first and the second regions of the body of the first stage particle is biodegradable.
- the first and the second regions of the body of the first stage particle may have different characteristic time for releasing the first and the second population of second stage particles.
- both characteristic time for releasing the first population of second stage particles from the first region and characteristic time for releasing the second population of second stage particles from the second region may be greater that a characteristic for delivery and/or localization of the first stage particle at its target site when administered to the subject.
- the first stage particle is configured to separate into a first component that includes the first region and a second component that includes the second region when being exposed to a physiological medium, such as a medium that may be present at a target site of the first stage particle. Such exposure may occur, for example, when the particle is administered to the subject.
- the first and the second regions of the body of the first stage particle are configured to perform a different function when the particle is administered to the subject.
- the first and the second region of the body of the first stage particle may be configured to overcome respectively the first and the second biological barriers that are different from each other.
- Such biological barriers may be each selected, for example, from a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
- the second stage particle may be any micro or nanoparticle that may fit inside the reservoir of the first stage particle.
- the second stage particle is the same as the first stage particle for intravascular administration.
- the particle of the second stage may be configured to overcome at least one barrier selected from a hemo-rheology barrier, a Reticulo-Endothelial System barrier, an endothelial barrier, a blood brain barrier, a tumor-associated osmotic interstitial pressure barrier, an ionic and molecular pump barrier, a cell membrane barrier, an enzymatic degradation barrier, a nuclear membrane barrier or a combination thereof.
- a hemo-rheology barrier a Reticulo-Endothelial System barrier
- an endothelial barrier a blood brain barrier
- a tumor-associated osmotic interstitial pressure barrier an ionic and molecular pump barrier
- a cell membrane barrier an enzymatic degradation barrier
- nuclear membrane barrier or a combination thereof.
- the second stage particle may be a lipid based particle, such as a liposome, a micelle or lipid encapsulated perfluorocarbon emulsion; an ethosome; a carbon nanotube, such as single wall carbon nanotube; a fullerene nanoparticle; a metal nanoparticle, such gold nanoshell or triangular silver nanoparticle; a semiconductor nanoparticle, such as quantum dot or boron doped silicon nanowire; a polymer nanoparticle, such as particles made of biodegradable polymers and ion doped polyacrylamide particles; an oxide nanoparticle, such as iron oxide particle, a polymer coated iron oxide nanoparticle or a silicon oxide particle; a viral particle, such as an engineered viral particle or an engineered virus-polymer particle; a polyionic particle, such as leashed polycations; a ceramic particle, such as silica based ceramic nanoparticles, or
- the second stage particle is configured to target a particular target site in a body of the subject.
- target site may be the same or different from the target site targeted by the first stage particle.
- the surface of the second stage particle may have one or more antibodies that may conjugate with surface marker antigens of certain types of cells.
- the second stage particle may selectively target cells that carry such marker antigens.
- the examples of cells that carry surface marker antigens include stem or clonogenic cells and tumor cells.
- the surface marker antigens on stem or clonogenic cells may be targeted by CD33 antibody.
- a number of monoclonal antibodies to tumor specific antigens are available, see, e.g., pp. 301-323 of CANCER, 3rd Ed., De Vita, et. al. eds; Janeway et. al. Immunology 5th Edition, Garland Press, New York, 2001; A. N. Nagappa, D. Mukherjee & K. Anusha “Therapeutic Monoclonal Antibodies”, PharmaBiz.com, Wednesday, Sep. 22, 2004. Table 2 presents FDA approved monoclonal antibodies for treatment of cancer.
- the second stage particle is configured to freely circulate in a blood system of the subject upon being released from the first stage particle.
- such second stage particle may have a surface free of targeting moieties, such as antibodies.
- the free circulating second stage particle may be used, for example, as to report of therapeutic action a therapeutic agent associated with a first stage particle per se.
- the surface of the second stage particle does not have hydrophilic polymer chains, such as polyethylene glycol (PEG) disposed on it.
- PEG polyethylene glycol
- this may be an advantage of the multistage delivery vehicle as PEG chains are usually attached to liposomes and other nanoparticles to delay recognition and sequestration by macrophages of the reticulo-endothelial system.
- the PEG chains may also hide antibodies on the nanoparticles surfaces and thus inhibit the targeting/localization ability of the antibodies.
- PEGs attached to the first stage particle may perform shielding from the RES macrophages.
- the recognition/localization capability of the first stage particle is not limited to the antibodies, as other factors such as the particle's size and shape also may contribute to such capability.
- the surface of the second stage particle has hydrophilic polymer chains, such as PEG chains, disposed on it.
- the surface of second stage particle is modified, for example, to facilitate the second stage particle's ability to load into a reservoir of the first stage particle and/or to facilitate the second stage particle's ability to reach its target site.
- the surface modification may include a chemical modification of the surface of the second stage particle and/or electrostatic modification of the surface of the second stage particle.
- the surface of the second stage particles may be modified so that its properties are compatible with surface properties of pores of the porous or nanoporous first stage particle.
- the pores of the porous or nanoporous first stage particle when the pores of the porous or nanoporous first stage particle are positively charged it may be preferably to modify the surface of the second stage particles so that they are electrostatically neutral or have a negative surface charge; while when the pores of the porous or nanoporous first stage particle are negatively charged, it may be preferably to modify the surface of the second stage particles so that they are electrostatically neutral or have a positive surface charge.
- the chemical and/or electrostatic surface modification of the second stage particles may be performed using the same methods as detailed above to the first stage particles.
- the electrostatic modification may be performed by incorporating in their lipid layers lipids that may affect the electrostatic charge of the liposome.
- lipids that may affect the electrostatic charge of the liposome.
- cationic lipids such as 1,2-Dioleyl-3-trymethylammoniumpropane (DOTAP)
- DOTAP 1,2-Dioleyl-3-trymethylammoniumpropane
- anionic lipids such as dioleoylphosphatidyl glycerol (DOPG)
- DOPG dioleoylphosphatidyl glycerol
- DOPC dioleoylphosphatidyl glycerol
- the second stage particle may release its content into the cell's cytoplasm.
- such release is activated by exogenous factors, such as electromagnetic radiation.
- exogenous factors such as electromagnetic radiation.
- such radiation may be radio-frequency radiation
- gold-shell nanoparticles the radiation may be a near-infrared radiation.
- Activation of nanoparticulates by exogenous radiation is detailed, for example, Hirsch, L. R., Halas, N. J. & West, J. L. Anal. Chem. 75, 2377-2381 (2003); Hirsch, L. R., Halas, N. J. & West, J. L. Proc. Natl. Acad. Sci. USA 100, 13549-13554 (2003); and O'Neal, D. P., Halas, N. J. & West, J. L. Cancer Lett. 209, 171-176 (2004).
- the content of the second stage particle is one or more active agents per se.
- the second stage particle contains inside a third stage particle, which itself contains inside one or more active agents.
- the third stage particle may be, for example, a particle, that is small enough to be able to cross a nuclear membrane of the targeted cell.
- the third stage particle may serve for delivering to the cell's nucleus an active agent, that may be an agent acting against nucleic acids or a gene therapeutic agent.
- the third stage particle may range from about 3 nm to about 10 nm.
- the ability to deliver nanoparticles in 3 nm to 10 nm size range may be one of the advantages of the multistage delivery vehicle as a conventional administration of such particles via injection usually results in their immediate globular clearance.
- the multistage vehicle includes a third stage.
- the third stage may be any nanoparticle that may fit inside the second stage particle.
- the third stage particle may be a lipid based particle, such as a liposome, a micelle or lipid encapsulated perfluorocarbon emulsion; an ethosome; a carbon nanotube, such as single wall carbon nanotube; a fullerene nanoparticle; a metal nanoparticle, such gold nanoshell or triangular silver nanoparticle; a semiconductor nanoparticle, such as quantum dot or boron doped silicon nanowire; a polymer nanoparticle, such as particles made of biodegradable polymers and ion doped polyacrylamide particles; an oxide nanoparticle, such as iron oxide particle, a polymer coated iron oxide nanoparticle or a silicon oxide particle; a viral particle, such as an engineered viral particle or an engineered virus-polymer particle; a polyionic particle, such as leashed polycations; a ceramic
- Later stage particles may be introduced into a earlier stage particle of an earlier stage by any appropriate technique.
- one may soak nanoporous earlier stage particles fabricated in a solution containing a carrying fluid and the later stage particles, which may enter pores of the earlier stage particle via capillary action and/or diffusion.
- the carrying fluid may be a liquid that is biologically non-harmful and that is neutral with respect to the earlier stage particle's material.
- An example of the carrying fluid may be phosphate buffer saline (PBS) or a deionized water.
- the solution may also contain one or more additional agents, such one or more additional therapeutic agents and one or more appropriate penetration enhancers, desired to be introduced in the first stage particle.
- To maximize a load of the later stage particles one may use a solution that has a saturated concentration of the later stage particles.
- the earlier stage particles may be introduced into the solution in a form of suspension.
- Preparation of Nanoporous Particles Suspension is Detailed, for Example, in U.S. Patent Application No. 2003/0114366. Pores of the nanoporous particles may be dried prior their submerging in the solution containing the later stage particles.
- the solution containing the later stage particles pores may be degassed prior to the introduction of the earlier stage particles. Then, the earlier stage particles may be submerged in the degassed solution in a sealed chamber. The earlier stage particles may be subjected to reduced pressure to ensure that trapped air is forced from the pores in the particles. Then the earlier stage particles may be fully immersed in the solution and the pressure in the sealed chamber may be elevated slightly above atmospheric to make sure that the solution enters the pores of the earlier stage particles. The earlier stage particles may then be trapped on a filter and dried using one of the three methods described below.
- the pressure within the chamber is reduced and then raised slightly above atmospheric pressure.
- drying is achieved by one or more of the following three methods.
- Water may be removed by evaporation under reduced pressure in a vacuum chamber, or by passage of a stream of warm air or an inert gas such as nitrogen over the surface particles collected on a filter, or by freeze drying.
- a flat heat exchanger may be placed in good thermal contact, e.g. directly below, the filter, on which the earlier stage particles have been collected.
- Refrigerant fluid at temperatures ranging from ⁇ 20° C. to ⁇ 60° C., such as Freon, or a cold liquid, such as liquid nitrogen, may be passed through the heat exchanger flowing into port and passing out port in order to freeze any water remaining within the pores. The pressure may be then reduced until all the water sublimes.
- a solution containing the earlier stage nanoporous particles, the later stage particles and a carrier liquid is prepared.
- the carrier liquid may be a physiological buffer, such as Tris-HCl.
- a concentration of the carrier liquid may be selected by using standard techniques to maximize loading of the later stage particle into the nanoporous earlier stage particles. For example, in some embodiments, for Tris-HCl, the optimal concentration may be selected from 1 to 500 mM.
- Geometrical properties of the later stage particles may be selected to be compatible pore properties of the nanoporous earlier stage particles, such as pore density, pore size, and pore orientation.
- loading of the later stage particle into the nanoporous earlier stage particles is facilitated by agitating the solution containing both the later stage and earlier stage particles.
- Such agitation may be performed by spinning the solution in a rotating wheel.
- Agitation conditions, such as a rotation speed of the rotating wheel, may be optimized using standard techniques to achieve a desired loading degree and/or loading time.
- loading of the later stage particles into the earlier stage nanoporous particles is controlled by varying a concentration of the later stage particles in the solution.
- the higher load may be achieved by using a higher concentration of the later stage particles in the solution.
- one may achieve a higher load of the later stage particles by using a concentration of the later stage particles, which is lower than the highest possible concentration of the later stage particles in the solution. Determining a concentration maximizing loading of the later stage particles in the nanoporous earlier stage particles may be performed using standard methods.
- loading of the later stage particles into the earlier stage nanoporous particles is controlled by modifying a pore surface of the nanoporous earlier stage particles and/or a surface of the later stage particles in order to make them more compatible.
- Such modifying may be performed by modifying surface chemical groups on either surface and/or by modifying an electrical charge on either surface.
- to achieve a higher load of the later stage particle one may use negatively charged surface of the later stage particles and positively charged porous surface of the earlier stage nanoporous particles or positively charged surface of the later stage particles and negatively charged porous surface of the earlier stage nanoporous particles.
- a pore surface of the nanoporous earlier stage particles and a surface of the later stage particles are modified with chemical groups compatible with each other.
- one of the pore surface of the nanoporous earlier stage particles and the surface of the later stage particles may be modified with carboxy groups; while the other may be modified with amino groups.
- the active agent may be a therapeutic agent, an imaging agent or a combination thereof.
- the active agent may be any appropriate agent that may be released from a particle containing it. The selection of the active agent depends on the application.
- the active agent When the active agent is not a particle of any stage per se, it may be introduced into particle using any appropriate technique.
- the active agent when the active agent is doxorubicin, it may be introduced in a liposome particle using a protocol detailed in Working Example 4.
- the active agent when the active agent is a particle of one of the stages of multistage delivery vehicle, the active agent may introduced using one of the methods disclosed above.
- the therapeutic agent may be any physiologically or pharmacologically active substance that may produce a desired biological effect in a targeted site in an animal, such as a mammal or a human.
- the therapeutic agent may be any inorganic or organic compound, without limitation, including peptides, proteins, nucleic acids, and small molecules, any of which may be characterized or uncharacterized.
- the therapeutic agent may be in various forms, such as an unchanged molecules, molecular complex, pharmacologically acceptable salt, such as hydrochloride, hydrobromide, sulfate, laurate, palmitate, phosphate, nitrite, nitrate, borate, acetate, maleate, tartrate, oleate, salicylate, and the like.
- salts of metals, amines or organic cations for example, quaternary ammonium
- derivatives of drugs such as bases, esters and amides also may be used as a therapeutic agent.
- a therapeutic agent that is water insoluble may be used in a form that is a water soluble derivative thereof, or as a base derivative thereof, which in either instance, or by its delivery, is converted by enzymes, hydrolyzed by the body pH, or by other metabolic processes to the original therapeutically active form.
- the therapeutic agent may be a chemotherapeutic agent, an immunosuppressive agent, a cytokine, a cytotoxic agent, a nucleolytic compound, a radioactive isotope, a receptor, and a pro-drug activating enzyme, which may be naturally occurring or produced by synthetic or recombinant methods, or any combination thereof.
- Drugs that are affected by classical multidrug resistance such as vinca alkaloids (e.g., vinblastine and vincristine), the anthracyclines (e.g., doxorubicin and daunorubicin), RNA transcription inhibitors (e.g., actinomycin-D) and microtubule stabilizing drugs (e.g., paclitaxel) may have particular utility as the therapeutic agent.
- vinca alkaloids e.g., vinblastine and vincristine
- anthracyclines e.g., doxorubicin and daunorubicin
- RNA transcription inhibitors e.g., actinomycin-D
- microtubule stabilizing drugs e.g., paclitaxel
- a cancer chemotherapy agents may be a preferred therapeutic agent.
- Useful cancer chemotherapy drugs include nitrogen mustards, nitrosorueas, ethyleneimine, alkane sulfonates, tetrazine, platinum compounds, pyrimidine analogs, purine analogs, antimetabolites, folate analogs, anthracyclines, taxanes, vinca alkaloids, topoisomerase inhibitors and hormonal agents.
- Exemplary chemotherapy drugs are Actinomycin-D, Alkeran, Ara-C, Anastrozole, Asparaginase, BiCNU, Bicalutamide, Bleomycin, Busulfan, Capecitabine, Carboplatin, Carboplatinum, Carmustine, CCNU, Chlorambucil, Cisplatin, Cladribine, CPT-11, Cyclophosphamide, Cytarabine, Cytosine arabinoside, Cytoxan, dacarbazine, Dactinomycin, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, DTIC, Epirubicin, Ethyleneimine, Etoposide, Floxuridine, Fludarabine, Fluorouracil, Flutamide, Fotemustine, Gemcitabine, Herceptin, Hexamethylamine, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Mechloreth
- Useful cancer chemotherapy drugs also include alkylating agents, such as Thiotepa and cyclosphosphamide; alkyl sulfonates such as Busulfan, Improsulfan and Piposulfan; aziridines such as Benzodopa, Carboquone, Meturedopa, and Uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as Chlorambucil, Chlomaphazine, Cholophosphamide, Estramustine, Ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, Melphalan, Novembiehin, Phenesterine, Prednimustine, Trofosfamide, uracil mustard; nitroureas such as Cannustine, Chlorozotocin, Fotem
- anti-hormonal agents that act to regulate or inhibit hormone action on tumors
- anti-estrogens including for example Tamoxifen, Raloxifene, aromatase inhibiting 4(5)-imidazoles, 4 Hydroxytamoxifen, Trioxifene, Keoxifene, Onapristone, And Toremifene (Fareston); and anti-androgens such as Flutamide, Nilutamide, Bicalutamide, Leuprolide, and Goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
- Cytokines may be also used as the therapeutic agent.
- cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- ⁇ and - ⁇ ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- ⁇ ; platelet growth factor; transforming growth factors (TGFs) such as TGF- ⁇ and T
- the imaging agent may be any substance that provides imaging information about a targeted site in a body of an animal, such as a mammal or a human being.
- the imaging agent may comprise magnetic material, such as iron oxide, for magnetic resonance imaging.
- the active agent may be, for example, semiconductor nanocrystal or quantum dot.
- the imaging agent may be metal, e.g., gold or silver, nanocage particles.
- the imaging agent may be also an ultrasound contrast agent, such as a micro or nanobubble or iron oxide micro or nanoparticle.
- the multistage delivery vehicle may be administered as a part of a composition, that includes a plurality of the vehicles, to a subject, such as human, via any suitable administration method in order to treat, prevent and/or monitor a physiological condition, such as a disease.
- a composition may be administered by one of the following routes: topical, parenteral, inhalation/pulmonary, oral, vaginal and anal.
- Embodiments of the multistage delivery vehicles may be particularly useful for oncological applications, i.e. for treatment and/or monitoring cancer or a condition, such as tumor associated with cancer.
- skin cancer may be treated and/or monitored by topical application of, preferably, a viscous suspension
- lung cancer may be treated and/or monitored by inhalation of an aerosolized aqueous microdevice suspension
- cervical cancer may be treated and/or monitored by vaginal administration of a microdevice suspension
- colon cancer may be treated and/or monitored by rectal administration of such a suspension.
- the majority of therapeutic applications may involve some type of parenteral administration, which includes intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) injection.
- Administration of the multistage delivery vehicles may be systemic or local.
- the non-parenteral examples of administration recited above, as well as i.m. and s.c. injections, are examples of local administration.
- Intravascular administration may be either local or systemic.
- Local intravascular delivery may be used to bring a therapeutic substance to the vicinity of a known lesion by use of guided catheter system, such as a CAT-scan guided catheter.
- General injection such as a bolus i.v. injection or continuous/trickle-feed i.v. infusion are typically systemic.
- the multistage delivery vehicle may be formulated as a suspension that contains a plurality of the vehicles.
- the vehicles are uniform in their dimensions and their content.
- the vehicles as described above may be suspended in any suitable aqueous carrier vehicle.
- a suitable pharmaceutical carrier is one that is non-toxic to the recipient at the dosages and concentrations employed and is compatible with other ingredients in the formulation. Preparation of suspension of microfabricated particles is disclosed, for example, in US patent application publication No. 20030114366.
- the multistage delivery vehicle may administered as a part of an oral composition made up of a plurality of the vehicles.
- the vehicles in the composition are uniform in dimensions, i.e. the first stage particles of each vehicle have the same or substantially the same dimension; the second stage particles of each vehicle have the same or substantially the same dimensions.
- the composition may be made by mixing the vehicles with suitable non-aqueous carriers, such as oil or micronized powder, and filled in unit dose amounts into standard enteric-coated capsules or, alternatively, compressed into tablets and coated with an enteric coating material.
- suitable non-aqueous carriers such as oil or micronized powder
- the composition may be coated with a protective polymer.
- This material may be applied by film coating technology to either tablets or capsules to protect the product from the effects of, or prevent release of drugs in, the gastric environment.
- Such coatings are those, which remain intact in the stomach, but may dissolve and release the contents of the dosage form once it reaches the small intestine.
- the purpose of an enteric coating may be to delay release of the first stage particle's content.
- enteric polymer may be cellulose acetate phthalate (CAP).
- CAP cellulose acetate phthalate
- PVAP polyvinyl acetate phthalate
- Another useful polymer may be polyvinyl acetate phthalate (PVAP), which is less permeable to moisture, more stable to hydrolysis and able to ionize at a lower pH than is CAP. These properties may allow more reliable release in the duodenum.
- PVAP polyvinyl acetate phthalate
- Another example of currently used polymers may be those based on methacrylic acid-methacrylic acid ester copolymers with acid ionizable groups. Represented among these are polymers having the tradename Eudragit available through Rohm Pharma.
- the enteric coating may be applied from about 0.5% by weight to about 10% by weight of the tablet or capsule.
- a less water-soluble polymer such as methylcellulose
- ChronSet® technology developed by ALZA Corporation may be used to release a bolus of the multistage delivery vehicles at designated times and at targeted sites after passage from the stomach into the small intestine.
- a suspension of the vehicles may be loaded into ChronSet capsules. After swallowing, the capsules pass intact through the stomach.
- the shell may be engineered to regulate the rate of water imbibition the osmotically permeable portion of the system.
- the osmotic engine may expand to push and separate two halves of the capsule.
- the length of the capsule halves may be specifically designed to produce separation at pre-selected times.
- the contents of each capsule may be expelled into the intestinal lumen at 2 to 20 hours after administration. Greater than 80% of contents (in this case a suspension of drug-filled microfabricated particles) may be expelled within 15 minutes time frame. This approach may provide a means of releasing the suspension of the vehicles at preselected areas of the small or large intestine.
- Such a system may be used to release the multistage delivery vehicles at sites in the small or large intestine that are optimal for binding, such as areas, which contain receptors for the muco-adhesive ligand grafted to the particles, and/or absorption, such as regions of the intestinal epithelium that are sensitive to the permeation enhancers contained inside the first stage particle.
- Particles were counted in a Z2 Coulter® Particle Counter and Size Analyzer (Beckman Coulter).
- the aperture size used for particle analysis was 50 ⁇ m.
- the lower and upper size limits for analysis were set at 1.8 and 3.6 ⁇ m.
- particles were suspended in the balanced electrolyte solution of the instrument (ISOTON® II Diluent) and counted. The total volume of original suspension of particles did not exceed 0.3% of the final analysis volume.
- Silicon microparticles in IPA were dried in a glass beaker kept on a hot plate (80-90° C.). Silicon particles were oxidized in piranha (1 volume H 2 O 2 and 2 volumes of H 2 SO 4 ). The particles sonicated after H 2 O 2 addition and then acid was added. The suspension was heated to 100-110° C. for 2 hours with intermittent sonication to disperse the particles. The suspension was then washed in DI water till the pH of the suspension is 5.5-6. Particles were then transferred to appropriate buffer, IPA or stored in water and refrigerated till further use.
- the oxidized particles Prior to the silanization process, the oxidized particles were hydroxylated in 1.5 M HNO 3 acid for approximately 1.5 hours (room temperature). Particles were washed 3-5 times in DI water (washing includes suspending in water and centrifuging, followed by the removal of supernatant and the repeating of the procedure).
- the particles were suspended in IPA (isopropyl alcohol) by washing them in IPA twice. They were then suspended in IPA containing 0.5% (v/v) of APTES (3-aminopropyltriethoxysilane) for 45 minutes at room temperature. The particles were then washed with IPA 4-6 times by centrifugation and stored in IPA refrigerated. Alternatively, they were aliquoted, dried and stored under vacuum and dessicant till further use.
- IPA isopropyl alcohol
- PEG was attached to the microparticles to provide a spacer for further coupling with anti-VEGFR2 antibody.
- Fmoc-PEG-NHS which provided the NHS ester for rapid coupling to amine groups and an Fmoc group to protect the amine on the PEG, was used.
- the 106-109 particles/ml of APTES modified microparticles were resuspended in PBS (pH7.2) and Fmoc-PEG-NHS at a concentration of 1-10 mM added to the particles.
- the antibody to VEGFR2 was conjugated with Alexa 488 using an antibody labeling kit from Invitrogen Corp.
- the fluorescent tag was conjugated to the antibody by following the procedure provided in the manual of the kit. 1 mg/ml of antibody was used for tagging. The amount of antibody conjugated to the fluorescent tag was determined by analyzing the antibody with a DU® 730 UV/Vis Spectrophotometer (Beckman Coulter Inc., CA, USA) at 280 and 494 nm. The amount of antibody conjugated was found to be 407 ⁇ g/ml.
- the different amounts of antibody used were 0.814, 0.407, and 0.163 ⁇ g, corresponding to 2.7, 1.35, and 0.54 ⁇ g/ml respectively, and exposed to UV light for 10-15 min to couple the amine groups present on the antibody to the attached crosslinker.
- FIG. 3 Panel A, presents results of time dynamics for loading carboxy modified quantum dots and amino modified quantum dots into APTES modified LP and SP silicon particles.
- FIG. 4 Panels A-D present results of time dynamics for loading carboxy modified quantum dots and amino modified dots into (Panel A) LP oxidized silicon particles; (Panel B) LP APTES modified silicon particles; (Panel C) SP oxidized silicon particles and (Panel D) SP APTES modified silicon particles.
- Each of Panels A-D also presents time dynamics for loading PEG-FITC single wall carbon nanotubes, as described below.
- 1.2 ⁇ 10 6 LP and SP oxidized silicon or APTES modified microparticles were combined with 2 ⁇ M Amino-PEG Q-dots or Carboxyl Q-dots in 200 mM TRIS-HCl pH 7.3 in a 80 ⁇ l final volume. Particles and Q-dots were incubated in a rotating wheel (20 rpm) and sampled out from the vial after 15, 30, 45 and 60 minutes at 25° C. After incubation, the samples were diluted with Tris 20 mM, pH 7.3 to 150 ⁇ l and promptly read at a FACScalibur flow cytometer for fluorescence intensity.
- 2.1 ⁇ 10 6 LP silicon microparticles either oxidized or APTES modified were combined with 2 ⁇ M Amino-PEG Q-dots or Carboxyl Q-dots respectively, in a TRIS-HCl 200 mM pH7.3 solution. Final incubation volume was 140 ⁇ l. Samples were incubated in a rotating wheel (20 rpm) for 15 minutes at 25° C. The microparticles were then washed in 1.4 mL deionized water (10 folds dilution), and centrifuged 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22 centrifuge.
- Particles pellet was resuspended in 70 ⁇ l of deionized water and 10 ⁇ l were taken out the vial, diluted with a TRIS 20 mM, pH 7.3 solution to 150 ⁇ l final volume. Sample's fluorescence was immediately read with Becton Dickinson FACScalibur flow cytometer and recorded as time 0 or loading fluorescence.
- the residual 60 ⁇ l were diluted 10 times into 600 ⁇ L of TRIS-HCL 20 mM NaCl 0.9% release buffer. 100 ⁇ l were taken out this solution and additionally diluted 5 times by aliquoting the sample into tubes pre filled with 400 uL TRIS-HCL 20 mM NaCl 0.9% release buffer. Final dilution at this point was 500 folds. Samples were put in a rotating wheel (20 rpm) for the given amount of time (15, 45, 90, 180, 360 and 1200 minutes) minutes at 37° C. At each time point the aliquots were centrifuged 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22 centrifuge.
- FIG. 5A presents time dynamics of release of amino-modified quantum dots from LP oxidized silicon particles.
- FIG. 5B presents time dynamics of release of carboxy modified quantum dots from APTES modified LP silicon particles.
- a concentration curve for PEG-FITC SWNTs in 20 mM TRIS-HCL pH 7.3 was determined using a SPECTRAmax fluorimeter. A serial dilution was performed, starting with 35 ng/ ⁇ l and proceeding by a factor of 1:2 down to minimum detectable amount of 107 pg/ ⁇ l. The aliquots were placed in a 96 well plate and the fluorescence was read using excitation at 485, and emission at 520. Fluorescence quenching was observed at the higher concentrations of SWNTs, as shown by their lower fluorescence.
- Particles pellet was re-suspended in 60 ⁇ l of deionized water and 10 ⁇ l were taken out the vial, diluted with a TRIS 20 mM, pH 7.3 solution to 150 ⁇ l final volume. Sample's fluorescence was immediately read with Becton Dickinson FACScalibur flow cytometer and recorded as time 0 or loading fluorescence.
- the residual 50 ⁇ l were diluted 10 times into 500 ⁇ L of TRIS-HCL 20 mM NaCl 0.9% release buffer. 100 ⁇ l were taken out this solution and additionally diluted 5 times by aliquoting the sample into tubes pre filled with 400 uL TRIS-HCL 20 mM NaCl 0.9% release buffer. Final dilution at this point was 500 folds. Samples were put in a rotating wheel (20 rpm) for the given amount of time (15, 45, 120, 240 and 1200 minutes) minutes at 37° C. At each time point the aliquots were centrifuged 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22 centrifuge.
- FIG. 5A presents time dynamics of release of PEG-FITC-SWNTs from LP oxidized silicon particles.
- FIG. 5B presents time dynamics of release of PEG-FITC-SWNTs from APTES modified LP silicon particles.
- LP and SP oxidized silicon microparticles were combined with 10 ng/ ⁇ l of liposomes, containing an Alexa fluo 555 conjugated siRNA, in a 20 mM TRIS-HCl pH7.3 solution.
- Particles and nanoliposomes were incubated in a rotating wheel (20 rpm) and sampled out from the vial after 15, 30 and 60 minutes at 25° C. After incubation, the samples were diluted with Tris 20 mM, pH 7.3 to 150 ⁇ l and promptly read at a FACScalibur flow cytometer for fluorescence intensity.
- 5 ⁇ 10 6 LP and SP oxidized silicon particles were either mixed in a solution containing 2.5 mM TRIS and 0.9% NaCl at pH 7.3 (Saline) or in cell culture media supplemented with 10% FBS (CCM). The mixture was incubated in a rotating wheel (8 rpm) at 37° C. and sampling for SEM, Z2 and ICP was performed at time 0 and after 6, 18 and 24 hours.
- the experiment was designed in order to have enough material to perform the three types of analysis for the degradation study in parallel at the same time, thus avoiding differences due to uncontrolled or unnoticed variables. This protocol therefore applied to the samples obtained for SEM, Z2 and ICP.
- porous Silicon particles disappeared from the solutions, they were incubated in, the porous Silicon particles were dissolved in Silicic Acid and studied by a technique called Inductive Coupled Plasma Atomic Emission Spectrometry (ICP-AES).
- ICP-AES Inductive Coupled Plasma Atomic Emission Spectrometry
- FCS foetal calf serum
- FCS foetal calf serum
- EGF epidermal growth factor
- -ECGF endothelial cell growth factor
- the plates were incubated at 37° C. and, at the time points of 12, 24, 48 and 72 hours, the toxicity assay was performed as described for the calibration assay with the exception of Triton addition. All the experiments were done in triplicate and results expressed as mean values with standard deviations.
- the plates were incubated at 37° C. and, at the time points of 12, 24, 48 and 72 hours, the medium was removed from the well and the cells extensively washed with sterile PBS to remove Silicon particles.
- the proliferation assay was then performed as described for the calibration assay. All the experiments were done in triplicate and results expressed as mean values with standard deviations.
- 0.6 ⁇ 10 6 cells were seeded in 25 cm 2 flasks and when the cells were attached (approximately 6 hours later, when the cells generated a 60% confluent cell bed), 3 ⁇ 10 6 of either LP oxidized, SP oxidized, LP APTES or SP APTES Silicon particles (1:5 ratio) resuspended in 20 ⁇ l of sterile, deionized H 2 O, were added to the medium of each flask.
- deionized H 2 O were added to the cells while as a negative control we added 50 ⁇ g/ml of Cis-platinum to cell culture media.
- the same amount of HUVEC cells was seeded in 75 cm 2 flasks to allow them to freely grow without reaching confluency during the experiment.
- a solution containing (50 ⁇ g/ml propidium iodide in 10 mM Tris, 5 mM MgCl 2 , pH 7.3 and 75 ⁇ g/ml RNAse) was then added to the cell pellet and the suspension was incubated in dark on a rotating wheel (5 rpm) for 60 minutes. Samples were then transferred into FACS tubes and immediately read with a Becton Dickinson flow cytometer.
- a polygonal region (R1) was defined around the centre of the population excluding the events that were to close to the noise signal of the instrument. For each sample, the number of particles detected in the R1 region was above 80%.
- MFI mean fluorescence intensity
- detectors used were forward scatter (FSC) E-1 and side scatter (SSC) with 474V voltage set.
- the fluorescent detector FL1 was set at 800V.
- Green fluorescence (FITC and Q-dots 525) was detected using FL1, 530/30 nm band-pass filter. Orange and red fluorescence (Q-dots D565 and Propidium Iodide) was detected using FL2. As single color detection only was being analyzed compensation was set at zero. Instrument calibration was carried out before, in between and after each series of acquisition using rainbow BD CalibriteTM beads.
- detectors used were linear forward scatter (FSC) E00 with an amplification gain of 4.59 and linear side scatter (SSC) with the voltage set at 474V with an amplification gain of 1.07.
- the fluorescent detectors FL2 was set at 449V with the amplification gain set at 1.32.
- Fluorescent imaging of particles was performed with a Nikon Eclipse TE2000-E with a DQC-FS Nikon CCD Camera kept at ⁇ 30.1° C. All the samples were mounted immediately before the analysis and the images acquired with a 63 ⁇ immersion oil objective. The microscope settings were kept constant throughout all the experiments. Numerical Aperture was set at 1.4, Refractive Index at 1.515, Exposure Time at 500 ms, Readout Speed at 10 MHz and Conversion Gain at 1 ⁇ 6 ⁇ . The images were analyzed and measured with the NIS Elements AR 2.3 Software.
- the total number of particles used for conjugating APTES modified particles with the anti-VEGFR2 was ⁇ 7.03 ⁇ 10 6 .
- Two different amounts of anti-VEGFR2 were used for the conjugation as listed in Table 3 below.
- Anti-VEGFR2 per Particles Amt. of Anti-VEGFR2 10 6 particles ID No. of particles ( ⁇ g) ( ⁇ g) APTES 1 7.42 ⁇ 10 5 0.065 0.088 APTES 2 7.42 ⁇ 10 5 0.022 0.03
- Qdots Quantum dots
- SWNT single-wall carbon nanotubes
- Q-dots are light-emitting semiconductor nanocrystal (CdSe or CdTe), and many research has been conducted on in-vitro and in-vivo molecular and cellular imaging because of their high brightness, photostability and the capacity of multiplexed color coding.
- Q-dots were coated with hydrophilic polyethylene glycol (PEG) to increase biocompability.
- the zeta potential was ⁇ 1 mV for Amino-PEG Qdots in 20 mM Trs buffer, and ⁇ 32.8 mV for carboxyl PEG Q-dots.
- the hydrodynamic size was measured by the diffusion coefficient of colloidals in solution using scattering light dynamic light scattering technique. Amino and Carboxyl Q-dots show similar hydrodynamics size (13 and 17 nm respectively).
- SWNT is well-ordered hollow “rolled-up” structures, and has high aspect ratio, high surface area, high mechanical strength, ultra light weight, excellent chemical/thermal stability.
- Many protocols have been studied to functionalize the SWNT surface with peptides, proteins and drugs.
- SWNT was of diameter 2-4 nm and lengths between 30 and 100 nm, the surface was functionalized with PEG-amine, providing solubility in water and physiological saline and further linked to FITC for fluorescent imaging.
- the zeta potential measurement shows ⁇ 9.2 mV in 20 nM TRIS buffer.
- Tris concentration was selected as a buffering agent because, it may give the highest stability to the quantum dots (Q-dots) compared to other buffering agents.
- Q-dots quantum dots
- the mean fluorescence of Q-dots loaded particles was studied as a function of Tris concentration. The fluorescence signal on the particles increased as the Tris concentration increases. The concentration of 200 mM Tris gave the best effect in terms of loading and was therefore selected for all the subsequent experiments.
- the loading capacity of “large porous” silicon particles was evaluated by using “small porous” silicon particles as the control.
- the hydrodynamic size of Q-dots is 13-15 nm, and should not be able to get into the small pores ( ⁇ 5 nm) but stay on their surface.
- the concentration effect of Q-dots for the loading was performed by changing the amount of Q-dots from 10 picomolar to 2 micromolar and incubating all the reactions in the same final volume (20 ⁇ l). Sample's loading was analyzed at FACS and the quantum dot concentration of 2 ⁇ M resulted in the highest level of loading and therefore used for all the subsequent experiments.
- the kinetics of amino quantum dots release from LP oxidized particles were exponential like with a 33% decrease of the amount of loaded nanoparticles after 20 minutes and of 67.5% after 45 minutes. After 20 hours only a residual 1% of the initial fluorescence was found associated to the particles demonstrating that all the quantum dots could be released from the nanoporous silicon particles.
- the fluorescence of a solution containing 35 ⁇ g/ml of FITC conjugated single wall carbon nanotubes (FITC-SWNTs) and of a serial dilution of them (ranging from 1:2 to 1:2048) in milliq pure water was measured ( FIG. 6A , Panel A).
- the fluorescence values of the first 3 and more concentrated samples were lower than the values of less concentrated solution. This is a phenomenon known as fluorescence quenching.
- As a control the same readings were performed with a series of solutions of carboxy pegylated quantum dots ranging from 8 ⁇ M to 4 nM that showed a linear decrease of the fluorescence value along with the dilution.
- Nanoliposomes also loaded into LP particles with the same dynamics as described above.
- the fluorescence associated with the Silicon particles were visualized by means of fluorescence microscopy ( FIG. 8A , Panels A and B, FIG. 8B , Panels E and F).
- Porous Silicon is known to be fully biodegradable (Mayne 2000; Low, Williams et al. 2006) and biocompatible (Canham 1995).
- the oxidation process that was performed according with protocols already described for Silicon wafers (Canham 1997), introduced hydroxil groups (OH) on the exposed Silicon surface and these groups, in the presence of water, are subjected to hydrolysis thus converting solid Silicon into highly soluble Silicic acid.
- the characterization of nanoporous Silicon particles degradation was performed through several techniques. The measurement of a decrease in the number of particles and in their volume was performed with Z2 Coulte® Particle Counter and Size Analyzer (Beckman Coulter). The particles were kept for 24 hours in a rotating wheel (8 rpm) at 37° C. in two different solution: TRIS 2.5 mM, 0.9% NaCl at pH7.3 (Saline) and Cell Culture Media with 10% FBS (CCM). To understand, if the size of the pores had a role in the degradation kinetics, both Silicon particles with smaller pores of 7-10 (SP) nanometers and particles with larger pores of 20-30 nanometers (LP) were used.
- SP 7-10
- LP nanometers
- the readings at the ICP showed a linear increase in the amount of silicon present after degradation. These data confirmed the ability of the ICP-AES method for verification of degradation. The data were regular, with low standard deviations, and had a strong correlation with the Z2 readings of particles count and size during the test. The increased degradation that occurred in cell culture media as opposed to TRIS buffer suggested high biodegradability of these particles in cell culture conditions ( FIG. 12A , Panels A-B and FIG. 12B , Panels C-D).
- Silicon nanoporous particles induced cell toxicity by means of Lactate Dehydrogenase (LDH) toxicity assay (Biovision Inc.), cell proliferation by means of MTT assay (Promega) and apoptosis and cell cycle by means of Propidium Iodide staining.
- LDH Lactate Dehydrogenase
- MTT MTT assay
- apoptosis and cell cycle by means of Propidium Iodide staining.
- FIG. 13 Panels A-D
- the cells were at 50% confluency after 12 hours and they reached almost 100% confluency after 24 hours.
- Some signs of apoptosis or, more generally, of cell death were visible at 48 hours and even more at 72 hours (bright, rounded, reflectant cells or cells with large, multilobular nuclei or with high narrowing of the cell body) as indicated by the white arrows in the FIG. 13 , Panels A-D. This was mainly due to the fact that the cells had already reached confluency and could not find any space to grow further and thus underwent some processes of cell degradation.
- LDH is a cytoplasmic enzyme that is released into the cytoplasm upon cell lysis.
- the LDH assay therefore, is a measure of membrane integrity.
- the basis of the LDH assay are oxidization of lactate to pyruvate by LDH, pyruvate reaction with the tetrazolium salt to form formazan, and the spectrophotometrical detection of the water-soluble formazan.
- a toxicity calibration curve ( FIG. 14A , Panel A) was made to correlate the absorbance values read at fluorimeter with the number of cells that were lysed by 1% Triton incubation. From this calibration curve, the amount of cells that were releasing the LDH enzyme during particles incubation was derived. At 12 and 24 hours, the toxicity signal was very low and could be mainly due to unbound cells that did not recover from trypsinization and seeding (background toxicity). This was confirmed by comparing the toxicity values coming from the experimental plates with those measured in the control plates ( FIG. 14A , Panel B). The toxicity of HUVEC cells grown in the 96 well plates without any particles (positive control) showed at 72 hours a mean absorbance of 0.496 at 470 nm.
- MTT is a yellow water-soluble tetrazolium dye that is reduced by live cells to a water insoluble purple formazan.
- the amount of formazan may be determined by solubilizing it in DMSO and measuring it spectrophotometrically. Comparisons between the spectra of treated and untreated cells may give a relative estimation of cytotoxicity. (Alley et al. (1988) Cancer Res. 48:589-601).
- a toxicity calibration curve ( FIG. 15 , Panel A) to correlate the absorbance values read at fluorimeter with the number of growing cells. From this calibration curve, the amount of cells that were metabolically active was derived.
- HUVEC cells exposed for 12, 24, 48 and 72 hours to a 1:5 ratio of particles were analyzed after fixation and propidium iodide staining at FACS.
- the forward scattering (FSC) and side scattering (SSC) in a dot plot and in a contour plot were first analyzed ( FIG. 16 , Panels A-C).
- FSC parameter provided an information of the size of the cells while SSC provided an information of the shape of the cells.
- HUVEC cells were incubated with CCM containing the degradation product of all the particles type and confirmed the results described so far ( FIG. 17D ).
- a slight increase was measured in the amount of cells in the apoptotic region when the cells were incubated for 72 hours with the degradation product of SP oxidized and SP and LP APTES modified particles. It may be possible that smaller Silicon fragments produced during the degradation process induced some kind of toxicity 45 -48.
- a multi-stage delivery system based on biodegradable silicon particles containing nanopores of specific size as first stage carriers that may load, carry, release and deliver into cells multiple types of nanoparticles with a precise control was developed.
- the first stage silicon nanoporous particles may be simultaneously loaded with different types of second stage nanoparticles, which are released in a sustained fashion over time.
- the major physical, chemical, and electrostatic mechanisms that control the loading and release of second stage nanoparticles were defined.
- the porous silicon carriers are able to locally delivery the second stage nanoparticles into the cytoplasm.
- nanotechnology Since its development in the last decade, nanotechnology has being used in a wide variety of applications in biomedical research for disease detection, diagnosis, and treatment 1-3 .
- the objectives of many studies involving the development and refinement of nanoparticles have focused on their use as agents for delivery of therapeutic or imaging molecules to organs, tissues, and cells 4,5 .
- a number of different nanovectors have been evaluated for therapeutic uses, including liposomes of various sizes and composition 6,7 , quantum dots (Q-dots) 8,9 , iron oxide 10 , single wall carbon nanotubes (SWNTs) 11 , gold nanoshells 12,13 and several other types of nanoparticles 14 .
- the progress thus far has given rise to the field defined as “molecularly targeted therapeutics” 15-18 , however the accomplishment of the original objective, which is to selectively deliver a therapeutic agent using a nanovector-based delivery system, has not been fully realized 19,20 .
- nanovectors into nanoporous silicon particles may allow the nanovectors to evade the natural biological barriers that may normally retard their therapeutic effects. Such approach may provide protection of therapeutic agents from surrounding fluids and molecules that may normally degrade them prematurely and from uptake by the Reticulo Endothelial System (RES). This may lead to a greater stability of the active agents, while providing increased delivery and concentrated dosage of therapeutic agents to a targeted tissue.
- RES Reticulo Endothelial System
- the multiple and simultaneous loading of second stage nanoparticles into first stage silicon nanoporous particles was achieved.
- the second stage particles (Q-dots and SWNTs) were slowly released over time periods sufficient for the first stage particle to reach a specific biological target site.
- the main physical, chemical and electrostatic mechanisms that govern the loading and release processes were.
- the nanodelivery system was able to locally release its payload into cells.
- FIG. 19 Panels a and b, show representative SEM images of the back and front sides and of the cross sections of “large pore” (LP) and “small pore” (SP) silicon particles respectively. These particles are highly porous and hemispherical in shape.
- the diameter of LP particles is approximately 3.5 ⁇ m, with pores of straight profile, which cross the particles perpendicularly to their external surface and have pore size ranging from 20 to 30 nm ( FIG. 19 , Panel a).
- SP silicon particles have a mean diameter of 3.2 ⁇ m, and have a flatter shape than LP silicon particles as a consequence of anodization and electropolishing processes used to produce them, with pore sizes less than 10 nm ( FIG. 19 , Panel b). Both LP and SP silicon particles have a thickness of 0.5-0.6 ⁇ m. According to BET analysis, the surface area is 156 m2 g-1 for LP particles and 294 m 2 g ⁇ 1 for SP particles. Pore volume is 0.542 cm 3 g ⁇ 1 for LP particles and 0.383 cm3 g-1 for SP particles.
- the pore density, size, shape and profile may be finely tuned by changing electrical current, etching time, and doping, which is reproducible from batch to batch.
- Non-oxidized silicon is a hydrophobic material but a variety of surface treatment protocols are available for silicon-based materials to be stabilized and further functionalized with oligonucleotides 27 , biomolecules 28 , antibodies 29,30 , and polyethylene glycol (PEG) chains 31 .
- Oxidized silicon particles have a negative zeta potential value ( ⁇ 10.1 for LP; ⁇ 11-25 for SP) due to the presence of the hydroxyl groups on the surface of the particles 32 .
- the particles that were modified with APTES have a positive zeta potential value (6.52 for LP; 6.45 for SP) as a consequence of the introduction of amino groups on their surface.
- the hydrodynamic size of Q-dots was measured by the diffusion coefficient of colloidal in solution using dynamic light scattering technique. Diameter was 13 nm for Amino-PEG Q-dots, and 16 nm for Carboxyl Q-dots. Size of PEG-FITC-SWNTs was evaluated by AFM microscopy. The diameter of non PEGylated SWNTs is around 1 nm but due to the PEG surrounding the nanotubes, PEG-FITC-SWNTs used for this study had a mean diameter of 4 nm, and a mean length of 30 nm. The SWNTs were functionalized using PEG-amine through carboxylic acids obtained via the SWNT cutting process and were conjugated to FITC to allow for their fluorescent imaging.
- Second stage nanoparticles with fluorescent properties were selected to quantify loading into and release from silicon nanoporous particles using established techniques, such as flow cytometry, fluorimetry, as well as both fluorescence and confocal microscopy. Physical and chemical of first and second stage particles are summarized in Table 6.
- Protocols to efficiently load nanoparticles inside the pores of first stage silicon particles were developed.
- One of the factors affecting the loading process was the amount of second stage particles in the media surrounding the particles.
- concentration of the second stage particles By raising the concentration of the second stage particles, progressively higher levels of loading were achieved as assessed by flow cytometry ( FIG. 20 , Panels A and B) and by direct visualization with fluorescent microscopy ( FIG. 20 , Panels C and D).
- FIG. 21 Panels a and c illustrate the results obtained when LP oxidized silicon particles and LP APTES modified silicon particles were incubated with a fixed amount of both Amino and Carboxyl Q-dots and PEG-FITC-SWNTs. Complete loading of the first stage porous silicon particles occurred within 15 min if the combination of first stage porous silicon particles and second stage particles matched the electrostatic criteria described above. The loading of SP oxidized silicon particles and SP APTES modified silicon particles with second stage nanoparticles was also evaluated ( FIG. 21 , Panels c and d, respectively).
- Q-dots size was between 13 and 16 nm so they could not be loaded into the pores of SP silicon particles (5-7 nm).
- the pores of LP silicon particles (20-40 nm) were sufficiently large to allow Q-dots loading.
- SP particle mean fluorescence was only 6% of LP particles.
- the smaller size of the PEG-FITC-SWNTs was compatible with SP particle pores, resulting in increased loading (25% of the PEG-FITC-SWNTs loaded into the LP silicon particles).
- FIG. 21 Panels e-h, demonstrate that both types of second stage particles were released over time from the first stage silicon particles. Surprisingly, the release process was sustained, with complete release reached after 20 hours. In addition, the release kinetics significantly differed between Q-dots and PEG-FITC-SWNTs, with Q-dots being released significantly faster than SWNTs.
- FIG. 22 Panels a-b, show a series of 3 dimensional projections and rotations of LP APTES silicon particles loaded with Carboxyl Q-dots. A more intense fluorescence signal was detected in the central region of the back face of the silicon particles, where larger pores are, see FIG. 19 , Panel a. The less intense signal coming from the surrounding areas was due either to partial loading into smaller pores or by the interaction of Q-dots with the surface of the silicon particle.
- Silicon is widely used in the microelectronics industry, and has demonstrated its capacity for mass production of microchips as well as for the development of biosensors, implantable devices, and drug delivery systems 36-39 . While bulk silicon remains inert in physiological buffer, porous silicon has a high degree of biodegradability with degradation kinetics that may be finely tuned between hours to days according to pore size density 40,41 . Porous silicon particles degrades to silicic acid, which is harmless to the body and we have found that neither whole intact silicon particles nor their degradation products are cytotoxic for cells.
- the fabrication protocols may allow the manufacturing of silicon particulates of any desired shape, size (dimensions from 100 nm to hundreds of ⁇ m), pore size (5-100 nm), and/or pore density.
- the present studies provide evidence of the ability of efficient loading of nanoporous silicon particles with second stage nanoparticles of different natures, sizes, and shapes.
- the loading process may be regulated by adjustment of the concentration of nanoparticles and/or by taking advantage of the chemical surface properties of either or both first and second stage particles.
- the dynamics of nanoparticle release and explored the ability of the nanoporous silicon particles to be loaded with multiple types of nanoparticles simultaneously has been shown in the present studies. These studies have clearly demonstrated that the Q-dots and PEG-FITC-SWNTs used as second stage particles may localize to different compartments of the first stage silicon nanoporous particle carriers according to the size and chemical properties of the second stage particles.
- the relative size of the pores of the silicon particles and of the second stage particles together may determine the most successful configuration of the combination of first and second stage particles ( FIG. 25 , Panel A). Concentration of the second stage nanovectors influences the efficiency of the loading process, which may be regulated both by passive diffusion and capillary convection of the second stage particles into the nanopores of the silicon particles. Hydrodynamic interactions of the second stage nanovectors with the nanopores of the silicon particles and Brownian motion affects stability of the assembled system and the time that the second stage nanovectors remain loaded inside the nanopores of the first stage silicon particles ( FIG. 25 , Panel B).
- a third mechanism that may be considered is the electrostatic interaction between the first stage silicon particle carrier and the second stage nanovectors ( FIG. 25 , Panel C).
- each of these features may allow the fine tuning of the amount of second stage nanovectors that may be loaded into the first stage nanoporous silicon particles, which may be matched to a specific pharmacological need in future applications of drug delivery.
- the original and unique properties of the multi-stage nanocarrier system may allow multiple therapeutic agents, penetration enhancers or imaging contrast agents to be delivered for the simultaneous detection and then destruction of tumors or for imaging and then treatment of other pathological conditions.
- a heavily doped p++type Si(100) wafer with a resistivity of 0.005 ohm cm ⁇ 1 (Silicon Quest International, Santa Clara, Calif., USA) was used as the substrate.
- the wafer was then placed in a home-make Teflon cell for electrochemical etching.
- the silicon particles with large pores (LP) were formed in a mixture of hydrofluoric acid (49% HF) and ethanol (3:7 v/v) by applying a current density of 80 mA cm ⁇ 2 for 25 s.
- a high porosity layer was formed by applying a current density of 320 mA cm ⁇ 2 for 6 s.
- SP silicon particles with small pores
- SP silicon particles with small pores
- the high porosity layers were formed by applying a current density of 320 mA cm ⁇ 2 for 6 s in an HF:ethanol mixture with a ratio of 2:5 (v/v). After removing the nitride layer by HF, particles were released by ultrasound in isopropyl alcohol (IPA) for 1 min. The IPA solution containing porous silicon particles was collected and stored at 4° C.
- the nitrogen adsorption desorption volumetric isotherms obtained at 77 K were measured on a Quantachrome Autosorb-3b BET Surface Analyzer. The samples were baked at 150° C. in vacuum overnight. Particle surface area was obtained by BET linearization in the pressure range 0.05 to 1 P/P0. For the LP particles, the BET surface area was 156 m 2 g ⁇ 1 and pore volume was 0.54 cm3 g-1 using nitrogen adsorption-desorption isotherm measurements. The average pore size was estimated to be about 24.2 nm. For SP particles, the BET surface area was measured 294 m 2 g-1; pore volume was 0.38 cm3 g 31 1 and the average pore size was 7.4 nm.
- Particles were counted using a Z2 Coulter® Particle Counter and Size Analyzer (Beckman Coulter, Fullerton, Calif., USA), with a 50 ⁇ m aperture size. The upper and lower size limits for analysis were set at 1.8 and 3.6 ⁇ m. For analysis, particles were suspended in the balanced electrolyte solution (ISOTON® II Diluent, Beckman Coulter Fullerton, Calif., USA) and counted. The total volume of original suspension of particles did not exceed 0.3% of the final analysis volume. The particle counter displays the concentration of particles in the solution as well an analysis of the particle size distribution.
- Silicon microparticles in IPA were dried in a glass beaker by heating (80-90° C.) and then oxidized them in a piranha solution (1:2 H 2 O 2 :concentrated H 2 SO 4 (v/v)).
- the particles were added to a solution of H 2 O 2 (30%), sonicated in a 5510R-MT ultrasonic cleaner (BRANSONIC, Danbury, Conn., USA) for 30 s and then H 2 SO 4 (95-98%) was added and the suspension was heated to 100-110° C. for 2 h, with intermittent sonication to disperse the particles.
- the particles were then washed with deionized (DI) water.
- DI deionized
- Washing of the particles in DI water involves centrifugation of the particulate suspension at 4,200 rpm for 5 min followed by removal of the supernatant and resuspension of the particles in DI water.
- the oxidized silicon particles were stored at 4° C. in DI water until further use.
- the oxidized silicon particles Prior to silanization, the oxidized silicon particles were hydroxylated in 1.5 M HNO 3 for approximately 1.5 h. The particles were then washed 3-5 times with DI water followed by 2 washes with IPA. The silicon particles were then suspended in IPA containing 0.5% (v/v) APTES for 45 min at room temperature. The particles were then washed with IPA (4,200 g for 5 min, 5 times), and stored in IPA at 4° C.
- Q-dots were purchased from Invitrogen (Carlsbad, Calif., USA). In this study, we used Amino-PEG with 525 nm and 565 nm emission wavelength (catalogue number Q21541MP and Q21531MP respectively) and Carboxyl Q-dots with 525 nm and 565 nm emission wavelength (catalogue number Q21341MP and Q21331MP respectively).
- Hydrazine monohydrate (10 mL) was added to and the solution was heated to reflux under nitrogen for 12 h to give a terminal primary amine on the end of the PEGylated US-SWNT.
- the product was purified by dialysis in DI water for 5 days.
- the solution was then transferred to a round bottom flask wrapped in foil and FITC (0.12 g) predissolved in a small amount of DMF was added to the H 2 H-PEG-US-SWNT solution.
- the reaction was stirred at room temperature for 12 h.
- the solution was transferred to a dialysis bag and was kept in continuous dialysis with DI water in the dark for 5 days followed by filtration through glass wool to remove the undissolved particulates.
- the final product FITC-PEG-US-SWNT contained some FITC physisorbed to the PEG-US-SWNTs instead of being covalently attached. Most of the physisorbed FITC still remains associated with the SWNTs after months of dialysis in water.
- the zeta potential of the silicon particles, Q-dots, and FITC-PEG-US-SWNTs were analyzed using a Zetasizer nano ZS (Malvern Instruments Ltd., Southborough, Mass., USA). The particles were suspended in 20 mM Tris(hydroxymethyl)aminomethane (TRIS-HCL) buffer (pH 7.3) for the analysis.
- TMS-HCL Tris(hydroxymethyl)aminomethane
- the silicon nanoporous particles that were used in development of the multi-stage nanodevice include LP oxidized porous silicon, SP oxidized porous silicon and APTES modified LP and SP particles.
- the second stage particles include Amino-PEG Q-dots, Carboxyl Q-dots, and PEG-FITC-SWNTs.
- Initial experiments were performed to titrate the loading of the second stage particles into the first stage silicon particles. For each experimental point of the titration experiments, 3.0 ⁇ 105 silicon particles were used, which were resuspended in low binding polypropylene micro centrifuge tubes (VWR International, West Chester, Pa., USA) containing 3 ⁇ l DI water.
- TRIS-HCl solution was adjusted at pH 7.3.
- Either 2 ⁇ M Q-dots (5 ⁇ l) or 20 ng/ ⁇ l PEG-FITC-SWNTs (9 ⁇ l) were added to the TRIS-HCl solution, with 20 ⁇ l as the final volume for the loading experiments.
- Samples were incubated by being placed on a rotating wheel (20 rpm) for 15 min at 25° C. After incubation, the samples were diluted with 20 mM TRIS-HCl, pH 7.3 to a volume of 150 ⁇ l and promptly examined for fluorescence intensity using a FACScalibur (Becton Dickinson) flow cytometer.
- FACScalibur Becton Dickinson
- LP silicon particles (2.1 ⁇ 106), which were either oxidized or APTES modified, were combined with 2 ⁇ M Amino-PEG Q-dots or Carboxyl Q-dots in a 200 mM TRIS-HCl solution at pH 7.3 or with 20 ng/ ⁇ l PEG-FITC-SWNTs in a 20 mM TRIS-HCl solution at pH 7.3 or with both 1 ⁇ M Q-dots and 10 ng/ ⁇ l PEG-FITC-SWNTs in a 50 mM TRIS-HCl solution at pH 7.3.
- the final incubation volume for all studies was 140 ⁇ l.
- first stage silicon particle carriers and second stage particles were incubated using a rotating wheel (20 rpm) for 15 min at 25° C.
- the solution containing the first stage silicon particles and second stage particles were then washed in 1.4 mL DI H 2 O, and then centrifuged for 5 min at 4,200 rpm in a Beckman Coulter Allegra X-22 centrifuge. Pellets present after centrifugation were then resuspended in 70 ⁇ l of DI H 2 O and 10 ⁇ l was removed from each vial to assess the fluorescence of the samples using flow cytometry. Fluorescence was recorded at time 0 and then over 6 time points, which included 30, 60, 90, 180, 360, and 1,200 min.
- the residual 60 ⁇ l left in each vial was diluted to 3 ml in 20 mM TRIS-HCl 0.9% NaCl release buffer, followed by incubation using a rotating wheel (20 rpm) for the given amount of time (30, 60, 90, 180, 360 and 1,200 min) at 37° C. At each time point, samples were centrifuged for 5 min at 4,200 rpm and the fluorescence evaluated using flow cytometry.
- Particles were assessed for fluorescence using a FACScalibur (Becton Dickinson). Bivariate dot-plots defining logarithmic side scatter (SSC) versus logarithmic forward scatter (FSC) were used to evaluate the size and shape of the silicon particles (3 ⁇ m in diameter, 1.5 ⁇ m in height) and to exclude non-specific events from the analysis. Control rainbow BD CalibriteTM beads (3.5 ⁇ m in size) were used to calibrate the instrument. A polygonal region (R1) was defined as an electronic gate around the centre of the major population of interest, which excluded events that were too close to the signal-to-noise ratio limits of the cytometer. For each sample, the number of particles detected within the R1 region was above 90%.
- GMFI geometric mean fluorescence intensity
- the morphology of the silica particles was acquired using scanning electron microscopy (SEM, model LEO1530). Particles were directly placed on SEM samples stage and dried. For the particles tested in the high salt buffers, a mild washing step in DI water was performed before putting on the stage. The acceleration voltage was 10 kV.
- AFM samples were prepared by deposition from DMF onto a freshly cleaved mica surface. Samples were spin coated and sectional analysis was used to determine the heights of each sample. AFM samples were obtained using tapping mode.
- Particles were analyzed in bright field contrast with an Olympus CKX41 microscope with a 40 ⁇ magnification lens. Images were taken with an SP-350 Olympus True-Pic TURBO Image Processor camera.
- Fluorescent imaging of particles was performed with a Nikon Eclipse TE2000-E with a DQC-FS Nikon CCD Camera kept at ⁇ 30.1° C. All the samples were mounted immediately before the analysis and the images acquired with a 63 ⁇ immersion oil objective. The microscope settings were kept constant throughout all the experiments. numerical aperture was set at 1.4, refractive index at 1.515, exposure time at 500 ms, readout Speed at 10 MHz and conversion gain at 1 ⁇ 6 ⁇ .
- Fluorescently labeled siRNA loaded DOPC liposomes (original siRNA concentration: 100 ng/ ⁇ l), as second stage particles, were mixed with 1st stage large pore “LP” oxidized silicon particles (3.5 micron). Incubation was performed in 20 mM Tris pH 7.3 for 30 min at room temperature. The solution was spun down at 4,200 rpm for 1 min at room temperature. The supernatant was recovered and the fluorescence of the sample was measured by fluorimetry using 544 nm/590 nm (excitation/emission) settings. The particle pellet comprising the 1st stage particles that had incorporated the fluorescent liposomes were resuspended in 100 ⁇ l of deionized water and fluorimetric readings were taken.
- FIG. 8B Panel D
- Panels E and F show fluorescent microscopy images visualizing second stage liposomes containing Alexa 555 labeled SiRNA into 3.5 micron nanoporous silicon first stage particles LP in white field and red field respectively
- Alexa 555 fluorescently labeled siRNAs were encapsulated into liposomes and loaded into the 1st stage porous silicon particles.
- Liposomes with a lipid composition of 58:40:2 Liposomes with a lipid composition of 58:40:2 (Mol %) DPPC:Cholesterol:DSPE-Methoxy PEG (2000) respectively may be made by the extrusion process as follows: Briefly, the lipids may be dissolved in ethanol at 55° C. The dissolved lipids may then be hydrated with 300 mM ammonium sulfate solution (for 15-30 minutes) to facilitate active loading of doxorubicin, see Li, et al. Biochim et Biophys Acta 1415 (1998). Liposomes may be extruded through a series of Nuclepore track-etched polycarbonate membranes of decreasing pore sizes.
- the liposomes may then be extruded 5 times through a 0.2 ⁇ m membrane. This may be followed by an extrusion through 0.1 ⁇ m membrane (5 times), then through a 0.05 ⁇ m membrane (5 times). The final extrusion may be through a 0.03 ⁇ m membrane (10 times). The extrusions may be carried out at 55° C.
- Produced fluorescently labeled liposomes contained 30% of DiPalmitoylPhosphatidylCholine (DPPC) lipids, 30% of cholesterol, 10% of fluorescently labeled lipid N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]dipalmitoyl-L- ⁇ -phosphatidylethanolamine (NBD-PE) lipid mixed with either 30% 1,2-Dioleyl-3-trymethylammoniumpropane (DOTAP) (for cationic liposomes), or 30% dioleoylphosphatidyl glycerol (DOPG) (for anionic liposomes), or 30% dioleoylphosphatidyl choline DOPC (for neutral liposomes).
- DOTAP 1,2-Dioleyl-3-trymethylammoniumpropane
- DOPG dioleoylphosphatidyl glycerol
- DOPG dioleoylphosphatidyl
- Neutral liposomes had initial mean diameter 47.4 nm and mean diameter after 3 days 78.2 nm as determined by Dynamic Light Scattering (DLS). Zeta potential of neutral liposomes was ⁇ 13.04 ⁇ 0.77 mV.
- Cationic liposomes had initial mean diameter 49.6 nm and mean diameter after 3 days 58.2 nm as determined by DLS. Zeta potential of cationic liposomes was 30.30 ⁇ 2.55 mV.
- FIG. 8A Panel A, shows confocal microscopy images of neutral (left) and cationic (right) fluorescently labeled liposomes loaded into 1 micron XLP APTES modified silicon particles.
- FIG. 8A , Panel C shows Excel quantification of fluorescently labeled liposome loading.
- the liposomes may be dialyzed overnight against 150 mM NaCl to remove unencapsulated ammonium sulfate to generate a trans-membrane proton gradient.
- Doxorubicin ( ⁇ 10 mg/ml) may be added to the liposomes at 60° C. for 1 hr. The drug:lipid ratio will be 0.2:1.0 and the final lipid concentration will be ⁇ 25 mM.
- the resulting liposomal formulation may be kept on ice for 15 minutes to stop the remote loading process.
- the liposomes may be dialyzed overnight against 150 mM NaCl to remove unencapsulated doxorubicin.
- the final encapsulated Doxorubicin concentration may be determined by lysis with methanol (30% of final volume) and measuring the UV absorbance at 480 nm.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/836,004 US20080311182A1 (en) | 2006-08-08 | 2007-08-08 | Multistage delivery of active agents |
KR1020097024739A KR20100051591A (ko) | 2007-04-27 | 2008-04-28 | 다공질 입자 및 이의 제조 방법 |
JP2010506558A JP2010526652A (ja) | 2007-04-27 | 2008-04-28 | 多孔性粒子およびその製造方法 |
AU2008245496A AU2008245496A1 (en) | 2007-04-27 | 2008-04-28 | Porous particles and methods of making thereof |
CN2008800220199A CN101778796B (zh) | 2007-04-27 | 2008-04-28 | 多孔颗粒及其制备方法 |
EP08780571A EP2150493A1 (fr) | 2007-04-27 | 2008-04-28 | Particules poreuses et leurs procédés de fabrication |
PCT/US2008/061775 WO2008134637A1 (fr) | 2007-04-27 | 2008-04-28 | Particules poreuses et leurs procédés de fabrication |
US12/110,515 US8920625B2 (en) | 2007-04-27 | 2008-04-28 | Electrochemical method of making porous particles using a constant current density |
CA2685544A CA2685544C (fr) | 2007-04-27 | 2008-04-28 | Particules poreuses et leurs procedes de fabrication |
JP2012196070A JP2013034991A (ja) | 2007-04-27 | 2012-09-06 | 多孔性粒子およびその製造方法 |
US14/538,065 US10253424B2 (en) | 2007-04-27 | 2014-11-11 | Porous particles and methods of making thereof |
US14/725,570 US10143658B2 (en) | 2006-08-08 | 2015-05-29 | Multistage delivery of active agents |
US16/158,644 US20190111000A1 (en) | 2006-08-08 | 2018-10-12 | Multistage delivery of active agents |
US17/368,401 US20210338593A1 (en) | 2006-08-08 | 2021-07-06 | Multistage delivery of active agents |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82175006P | 2006-08-08 | 2006-08-08 | |
US91434807P | 2007-04-27 | 2007-04-27 | |
US11/836,004 US20080311182A1 (en) | 2006-08-08 | 2007-08-08 | Multistage delivery of active agents |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/110,515 Continuation-In-Part US8920625B2 (en) | 2007-04-27 | 2008-04-28 | Electrochemical method of making porous particles using a constant current density |
US14/725,570 Continuation US10143658B2 (en) | 2006-08-08 | 2015-05-29 | Multistage delivery of active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080311182A1 true US20080311182A1 (en) | 2008-12-18 |
Family
ID=39082940
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/836,004 Abandoned US20080311182A1 (en) | 2006-08-08 | 2007-08-08 | Multistage delivery of active agents |
US14/725,570 Active US10143658B2 (en) | 2006-08-08 | 2015-05-29 | Multistage delivery of active agents |
US16/158,644 Abandoned US20190111000A1 (en) | 2006-08-08 | 2018-10-12 | Multistage delivery of active agents |
US17/368,401 Pending US20210338593A1 (en) | 2006-08-08 | 2021-07-06 | Multistage delivery of active agents |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/725,570 Active US10143658B2 (en) | 2006-08-08 | 2015-05-29 | Multistage delivery of active agents |
US16/158,644 Abandoned US20190111000A1 (en) | 2006-08-08 | 2018-10-12 | Multistage delivery of active agents |
US17/368,401 Pending US20210338593A1 (en) | 2006-08-08 | 2021-07-06 | Multistage delivery of active agents |
Country Status (9)
Country | Link |
---|---|
US (4) | US20080311182A1 (fr) |
EP (1) | EP2056794A4 (fr) |
JP (1) | JP2010500375A (fr) |
CN (1) | CN101652126B (fr) |
AU (1) | AU2007286203B2 (fr) |
CA (1) | CA2664919A1 (fr) |
HK (1) | HK1140139A1 (fr) |
MX (1) | MX2009001461A (fr) |
WO (1) | WO2008021908A2 (fr) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080102030A1 (en) * | 2006-10-11 | 2008-05-01 | Decuzzi Paolo | Particles for cell targeting |
US20080206344A1 (en) * | 2007-02-26 | 2008-08-28 | Board Of Regents Of The University Of Texas System | Endocytotic particles |
US20080280140A1 (en) * | 2007-04-27 | 2008-11-13 | Mauro Ferrari | Porous particles and methods of making thereof |
US20100209538A1 (en) * | 2009-02-18 | 2010-08-19 | Cipolla David C | Ph-modulated formulations for pulmonary delivery |
US20100285052A1 (en) * | 2009-05-05 | 2010-11-11 | Mullis Kary B | Chemically Programmable Immunity |
US20110070307A1 (en) * | 2004-12-17 | 2011-03-24 | Evgenia Mandrusov | Tissue regeneration |
WO2011038111A1 (fr) * | 2009-09-23 | 2011-03-31 | Crystalplex Corporation | Nanoparticules passivées |
WO2011086210A1 (fr) * | 2009-12-22 | 2011-07-21 | Universidad Autónoma de Madrid | Particules magnético-luminescentes pour applications biomédicales |
US20110213193A1 (en) * | 2008-08-28 | 2011-09-01 | The Florida International University Board Of Trustees | Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier |
WO2011116219A1 (fr) * | 2010-03-17 | 2011-09-22 | Board Of Regent Of The University Of Texas System | Systèmes d'administration à visée théranostique à surfaces modifiées |
US20110311452A1 (en) * | 2008-12-23 | 2011-12-22 | Board Of Regents Of The University Of Texas System | Inflammation targeting particles |
WO2012040331A2 (fr) * | 2010-09-21 | 2012-03-29 | The General Hospital Corporation | Nanoparticules multicouches |
US20120121516A1 (en) * | 2009-07-17 | 2012-05-17 | Centre National De La Recherche Scientifique- Cnrs | Emulsion Activatable by Ultrasounds and Method for Producing Same |
WO2012074440A2 (fr) * | 2010-12-01 | 2012-06-07 | Учреждение Российской Академии Наук Институт Кристаллографии Им. А.В.Шубникова Ран | Composition pharmacologique destinée à être administrée par voie intranasale en vue d'amener au cerveau un composant pharmacologiquement actif, et procédé de préparation de cette composition |
US20130195759A1 (en) * | 2008-04-25 | 2013-08-01 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
US20130195963A1 (en) * | 2011-12-07 | 2013-08-01 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
US8568877B2 (en) | 2010-03-09 | 2013-10-29 | Board Of Regents Of The University Of Texas System | Porous and non-porous nanostructures |
US20140010879A1 (en) * | 2012-06-12 | 2014-01-09 | The Methodist Hospital Research Institute | Compositions and methods of treating therapy resistant cancer and uses thereof |
WO2014036019A2 (fr) * | 2012-08-27 | 2014-03-06 | Red Lion Chem Tech, Llc | Procédés et compositions pour l'élimination des métaux lourds et pour administrer des agents souhaitables par voie orale |
US20140127305A1 (en) * | 2011-04-14 | 2014-05-08 | The Regents Of The University Of California | Multifunctional nanoparticle designs and applications |
US8808733B2 (en) | 2009-03-31 | 2014-08-19 | The Board Of Trustees Of The University Of Arkansas | Method of controlled drug release from a liposome carrier |
US20140296836A1 (en) * | 2011-09-27 | 2014-10-02 | Board Of Regents, The University Of Texas System | Gold-in-silicon nanoassembly for thermal therapy and methods of use |
US8859004B2 (en) | 2011-08-04 | 2014-10-14 | Nano And Advanced Materials Institute Limited | pH-sensitive nanoparticles for oral insulin delivery |
US20140356441A1 (en) * | 2013-05-31 | 2014-12-04 | Ricoh Company, Ltd. | Core-shell type particles and method for producing the same |
US9028797B2 (en) | 2010-02-26 | 2015-05-12 | Nagasaki University | Composite body for antigen or drug delivery |
US9101547B2 (en) | 2011-08-04 | 2015-08-11 | Nano And Advanced Materials Institute Limited | Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery |
WO2015176025A1 (fr) | 2014-05-15 | 2015-11-19 | The Methodist Hospital | Nanoconstructions polymères discoïdes et méthodes d'utilisation dans la théranostique du cancer |
US9216155B2 (en) | 2010-01-19 | 2015-12-22 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
WO2015066212A3 (fr) * | 2013-10-31 | 2015-12-30 | University Of Hawaii | Inhibiteurs de la calpaïne destinés au traitement de la maladie inflammatoire chronique de l'intestin et du cancer colorectal |
US9541480B2 (en) | 2011-06-29 | 2017-01-10 | Academia Sinica | Capture, purification, and release of biological substances using a surface coating |
US20170056327A1 (en) * | 2015-08-25 | 2017-03-02 | The Methodist Hospital | Micro/nano composite drug delivery formulations and uses thereof |
US20170136123A1 (en) * | 2013-01-10 | 2017-05-18 | Amrita Vishwa Vidyapeetham | Stannous doped micro and nano particles for augmented radiofrequency ablation |
US9849087B2 (en) | 2011-11-08 | 2017-12-26 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
US10058633B2 (en) | 2010-07-09 | 2018-08-28 | Board Of Regents Of The University Of Texas System | Biodegradable scaffolds |
US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
US10112198B2 (en) | 2014-08-26 | 2018-10-30 | Academia Sinica | Collector architecture layout design |
US10182988B2 (en) | 2013-12-03 | 2019-01-22 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US10208310B2 (en) | 2014-10-06 | 2019-02-19 | Exicure, Inc. | Anti-TNF compounds |
WO2019157319A1 (fr) * | 2018-02-12 | 2019-08-15 | Flagship Pioneering Innovations V, Inc. | Dispositifs et procédés pour administrer une matière dans un tissu biologique ou une cellule |
US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US10495644B2 (en) | 2014-04-01 | 2019-12-03 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
US10736845B2 (en) | 2015-03-03 | 2020-08-11 | Cureport Inc. | Dual loaded liposomal pharmaceutical formulations |
US10837018B2 (en) | 2013-07-25 | 2020-11-17 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10995267B2 (en) | 2014-05-29 | 2021-05-04 | Crystalplex Corporation | Dispersion system for quantum dots having organic coatings comprising free polar and non-polar groups |
US20210205456A1 (en) * | 2012-09-19 | 2021-07-08 | Georgetown University | Targeted liposomes |
US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US11510995B2 (en) * | 2015-12-21 | 2022-11-29 | Fidia Farmaceutici S.P.A. | Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes |
US11633503B2 (en) | 2009-01-08 | 2023-04-25 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
US11690920B2 (en) | 2017-07-13 | 2023-07-04 | Northwestern University | General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11859118B2 (en) | 2016-05-19 | 2024-01-02 | Tectus Corporation | Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3D structure containing them and methods of making and using them |
US11866700B2 (en) | 2016-05-06 | 2024-01-09 | Exicure Operating Company | Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA |
US12115229B2 (en) | 2015-12-21 | 2024-10-15 | Fidia Farmaceutici S.P.A. | Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006033679A2 (fr) | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Systeme d'administration de medicaments a base de nanoparticules a autoassemblage |
EP2018156B1 (fr) | 2006-04-07 | 2010-03-17 | Chimeros, Inc. | Compositions et procédés visant à traiter des malignités de cellules b |
KR20110039466A (ko) * | 2008-07-29 | 2011-04-18 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 미리 선택된 세포 내재화 방식을 갖는 입자 조성물 |
US8173115B2 (en) | 2008-07-29 | 2012-05-08 | The Board Of Regents Of The University Of Texas System | Particle compositions with a pre-selected cell internalization mode |
AU2009337181A1 (en) * | 2009-01-15 | 2011-08-04 | Board Of Regents Of The University Of Texas System | Porous structures with modified biodegradation kinetics |
WO2010120874A2 (fr) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation |
JP5968317B2 (ja) * | 2010-08-16 | 2016-08-10 | オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション | 生体分子を送達するためのセラミック粒子を含む粒子状物質 |
CA2847888A1 (fr) | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Procedes et compositions de regulation d'un assemblage de proteines virales |
US20130304050A1 (en) * | 2012-05-10 | 2013-11-14 | Wake Forest University Health Sciences | Methods of treating cancerous tissue |
CA2912975A1 (fr) * | 2012-10-16 | 2014-04-24 | William Marsh Rice University | Systeme d'administration de medicament a base d'un nanovecteur ameliore pour surmonter la resistance a un medicament |
KR101799557B1 (ko) | 2014-07-22 | 2017-11-20 | 주식회사 레모넥스 | 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도 |
EA035898B1 (ru) | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Композиции и способы для ингибирования биологической активности растворимых биомолекул |
JP6894423B2 (ja) * | 2015-07-09 | 2021-06-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 融合性リポソーム被覆多孔質ケイ素ナノ粒子 |
EP3426301A4 (fr) * | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | Nanoparticules composites et utilisations desdites nanoparticules |
EP3565604A4 (fr) * | 2017-01-04 | 2020-09-09 | Nanotics, LLC | Procédés d'assemblage de particules éliminatrices |
AU2018216591B2 (en) | 2017-02-06 | 2021-07-22 | Lemonex Inc. | Physiologically active substance carrier |
US20200163885A1 (en) * | 2017-07-25 | 2020-05-28 | Lemonex Inc. | Composition for delivering physiologically active ingredients into blood vessel |
KR102152348B1 (ko) | 2017-09-05 | 2020-09-08 | 주식회사 레모넥스 | 세포 운명 조절용 조성물 |
IL275409B2 (en) | 2017-12-19 | 2024-02-01 | Nanobiotix | Nano-particles for use to improve brain performance or to treat stress |
IL275408B2 (en) | 2017-12-19 | 2024-06-01 | Nanobiotix | Nanoparticles for use in the treatment of neurological disorders |
CN112546406B (zh) * | 2020-11-20 | 2022-04-22 | 广东药科大学 | 一种微型机器人给药装置及给药系统 |
WO2024035784A1 (fr) * | 2022-08-10 | 2024-02-15 | Auburn University | Nanomatériau rétractable pour applications biomédicales |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099864A (en) * | 1994-12-02 | 2000-08-08 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | In situ activation of microcapsules |
US6107102A (en) * | 1995-06-07 | 2000-08-22 | Regents Of The University Of California | Therapeutic microdevices and methods of making and using same |
US6355270B1 (en) * | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
US20030059386A1 (en) * | 2001-09-27 | 2003-03-27 | Ceramoptec Industries, Inc. | Topical application of chromophores for hair removal |
US20030114366A1 (en) * | 1999-01-11 | 2003-06-19 | Francis J. Martin | Microfabricated particles and method for treating solid tumors |
US20050178287A1 (en) * | 1998-11-20 | 2005-08-18 | The General Hospital Corporation | Permanent, removable tissue markings |
US20080280140A1 (en) * | 2007-04-27 | 2008-11-13 | Mauro Ferrari | Porous particles and methods of making thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
US4933185A (en) | 1986-09-24 | 1990-06-12 | Massachusetts Institute Of Technology | System for controlled release of biologically active compounds |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US6395302B1 (en) * | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
ES2130056B1 (es) * | 1997-01-16 | 2000-02-01 | Lipotec Sa | Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion. |
US6887493B2 (en) * | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
US7563451B2 (en) * | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
KR20090007275A (ko) | 2005-12-20 | 2009-01-16 | 더 오하이오 스테이트 유니버시티 리서치 파운데이션 | 분석방법용 나노다공성 기판 |
WO2008054874A2 (fr) * | 2006-05-12 | 2008-05-08 | Brown University | Particules présentant une charge uniforme élevée de nanoparticules et procédés de préparation de celles-ci |
WO2008041970A2 (fr) | 2006-09-28 | 2008-04-10 | Board Of Regents Of The University Of Texas System | Procédés et compositions pour cibler un système vasculaire fenêtré |
US8563022B2 (en) * | 2006-10-11 | 2013-10-22 | Board Of Regents Of The University Of Texas System | Particles for cell targeting |
-
2007
- 2007-08-08 AU AU2007286203A patent/AU2007286203B2/en active Active
- 2007-08-08 CN CN2007800374243A patent/CN101652126B/zh active Active
- 2007-08-08 WO PCT/US2007/075516 patent/WO2008021908A2/fr active Application Filing
- 2007-08-08 US US11/836,004 patent/US20080311182A1/en not_active Abandoned
- 2007-08-08 CA CA002664919A patent/CA2664919A1/fr not_active Abandoned
- 2007-08-08 EP EP07840796A patent/EP2056794A4/fr not_active Withdrawn
- 2007-08-08 MX MX2009001461A patent/MX2009001461A/es active IP Right Grant
- 2007-08-08 JP JP2009523983A patent/JP2010500375A/ja active Pending
-
2010
- 2010-06-30 HK HK10106383.0A patent/HK1140139A1/xx unknown
-
2015
- 2015-05-29 US US14/725,570 patent/US10143658B2/en active Active
-
2018
- 2018-10-12 US US16/158,644 patent/US20190111000A1/en not_active Abandoned
-
2021
- 2021-07-06 US US17/368,401 patent/US20210338593A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099864A (en) * | 1994-12-02 | 2000-08-08 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | In situ activation of microcapsules |
US6107102A (en) * | 1995-06-07 | 2000-08-22 | Regents Of The University Of California | Therapeutic microdevices and methods of making and using same |
US20050178287A1 (en) * | 1998-11-20 | 2005-08-18 | The General Hospital Corporation | Permanent, removable tissue markings |
US6355270B1 (en) * | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
US20030114366A1 (en) * | 1999-01-11 | 2003-06-19 | Francis J. Martin | Microfabricated particles and method for treating solid tumors |
US20030059386A1 (en) * | 2001-09-27 | 2003-03-27 | Ceramoptec Industries, Inc. | Topical application of chromophores for hair removal |
US20080280140A1 (en) * | 2007-04-27 | 2008-11-13 | Mauro Ferrari | Porous particles and methods of making thereof |
Cited By (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110070307A1 (en) * | 2004-12-17 | 2011-03-24 | Evgenia Mandrusov | Tissue regeneration |
US8563022B2 (en) * | 2006-10-11 | 2013-10-22 | Board Of Regents Of The University Of Texas System | Particles for cell targeting |
US20080102030A1 (en) * | 2006-10-11 | 2008-05-01 | Decuzzi Paolo | Particles for cell targeting |
US8361508B2 (en) | 2007-02-26 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Endocytotic particles |
US20080206344A1 (en) * | 2007-02-26 | 2008-08-28 | Board Of Regents Of The University Of Texas System | Endocytotic particles |
US8920625B2 (en) | 2007-04-27 | 2014-12-30 | Board Of Regents Of The University Of Texas System | Electrochemical method of making porous particles using a constant current density |
US10253424B2 (en) | 2007-04-27 | 2019-04-09 | Board Of Regents Of The University Of Texas System | Porous particles and methods of making thereof |
US20080280140A1 (en) * | 2007-04-27 | 2008-11-13 | Mauro Ferrari | Porous particles and methods of making thereof |
US9532948B2 (en) * | 2008-04-25 | 2017-01-03 | Northwestern University | Nanostructure suitable for sequestering cholesterol and other molecules |
US20130195759A1 (en) * | 2008-04-25 | 2013-08-01 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
US20110213193A1 (en) * | 2008-08-28 | 2011-09-01 | The Florida International University Board Of Trustees | Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier |
US20110311452A1 (en) * | 2008-12-23 | 2011-12-22 | Board Of Regents Of The University Of Texas System | Inflammation targeting particles |
US11633503B2 (en) | 2009-01-08 | 2023-04-25 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
WO2010096242A1 (fr) * | 2009-02-18 | 2010-08-26 | Aradigm Corporation | Formulations modulées par le ph destinées à une administration pulmonaire |
US20100209538A1 (en) * | 2009-02-18 | 2010-08-19 | Cipolla David C | Ph-modulated formulations for pulmonary delivery |
RU2606175C2 (ru) * | 2009-02-18 | 2017-01-10 | Арадайм Корпорейшн | pН-МОДУЛИРОВАННЫЕ СОСТАВЫ ДЛЯ ДОСТАВКИ В ЛЕГКИЕ |
US8808733B2 (en) | 2009-03-31 | 2014-08-19 | The Board Of Trustees Of The University Of Arkansas | Method of controlled drug release from a liposome carrier |
US8604184B2 (en) * | 2009-05-05 | 2013-12-10 | The United States Of America As Represented By The Secretary Of The Air Force | Chemically programmable immunity |
US20100285052A1 (en) * | 2009-05-05 | 2010-11-11 | Mullis Kary B | Chemically Programmable Immunity |
US20120121516A1 (en) * | 2009-07-17 | 2012-05-17 | Centre National De La Recherche Scientifique- Cnrs | Emulsion Activatable by Ultrasounds and Method for Producing Same |
WO2011038111A1 (fr) * | 2009-09-23 | 2011-03-31 | Crystalplex Corporation | Nanoparticules passivées |
US9425253B2 (en) | 2009-09-23 | 2016-08-23 | Crystalplex Corporation | Passivated nanoparticles |
US11656231B2 (en) | 2009-09-23 | 2023-05-23 | Tectus Corporation | Passivated nanoparticles |
ES2367959A1 (es) * | 2009-12-22 | 2011-11-11 | Centro De Investigación Biomédica En Red En Bioingeniería, Biomateriales Y Nanomedicina | Particulas magnético-luminiscentes para aplicaciones biomédicas. |
WO2011086210A1 (fr) * | 2009-12-22 | 2011-07-21 | Universidad Autónoma de Madrid | Particules magnético-luminescentes pour applications biomédicales |
US10328026B2 (en) | 2010-01-19 | 2019-06-25 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
US11285106B2 (en) | 2010-01-19 | 2022-03-29 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
US9216155B2 (en) | 2010-01-19 | 2015-12-22 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
US9028797B2 (en) | 2010-02-26 | 2015-05-12 | Nagasaki University | Composite body for antigen or drug delivery |
US8568877B2 (en) | 2010-03-09 | 2013-10-29 | Board Of Regents Of The University Of Texas System | Porous and non-porous nanostructures |
WO2011116237A1 (fr) * | 2010-03-17 | 2011-09-22 | Board Of Regents Of The University Of Texas System | Théranostiques universels gérés par des cellules |
WO2011116219A1 (fr) * | 2010-03-17 | 2011-09-22 | Board Of Regent Of The University Of Texas System | Systèmes d'administration à visée théranostique à surfaces modifiées |
US10058633B2 (en) | 2010-07-09 | 2018-08-28 | Board Of Regents Of The University Of Texas System | Biodegradable scaffolds |
WO2012040331A3 (fr) * | 2010-09-21 | 2012-07-12 | The General Hospital Corporation | Nanoparticules multicouches |
WO2012040331A2 (fr) * | 2010-09-21 | 2012-03-29 | The General Hospital Corporation | Nanoparticules multicouches |
RU2475233C2 (ru) * | 2010-12-01 | 2013-02-20 | Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН | Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения |
WO2012074440A2 (fr) * | 2010-12-01 | 2012-06-07 | Учреждение Российской Академии Наук Институт Кристаллографии Им. А.В.Шубникова Ран | Composition pharmacologique destinée à être administrée par voie intranasale en vue d'amener au cerveau un composant pharmacologiquement actif, et procédé de préparation de cette composition |
WO2012074440A3 (fr) * | 2010-12-01 | 2012-08-23 | Учреждение Российской Академии Наук Институт Кристаллографии Им. А.В.Шубникова Ран | Composition pharmacologique destinée à être administrée par voie intranasale en vue d'amener au cerveau un composant pharmacologiquement actif, et procédé de préparation de cette composition |
US9744141B2 (en) | 2011-04-14 | 2017-08-29 | The Regents Of The University Of California | Multifunctional nanoparticle designs and applications |
US9089498B2 (en) * | 2011-04-14 | 2015-07-28 | The Regents Of The University Of California | Multifunctional nanoparticle designs and applications |
US20140127305A1 (en) * | 2011-04-14 | 2014-05-08 | The Regents Of The University Of California | Multifunctional nanoparticle designs and applications |
US11674958B2 (en) | 2011-06-29 | 2023-06-13 | Academia Sinica | Capture, purification, and release of biological substances using a surface coating |
US9541480B2 (en) | 2011-06-29 | 2017-01-10 | Academia Sinica | Capture, purification, and release of biological substances using a surface coating |
US8859004B2 (en) | 2011-08-04 | 2014-10-14 | Nano And Advanced Materials Institute Limited | pH-sensitive nanoparticles for oral insulin delivery |
US9101547B2 (en) | 2011-08-04 | 2015-08-11 | Nano And Advanced Materials Institute Limited | Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery |
US20140296836A1 (en) * | 2011-09-27 | 2014-10-02 | Board Of Regents, The University Of Texas System | Gold-in-silicon nanoassembly for thermal therapy and methods of use |
US10220000B2 (en) | 2011-11-08 | 2019-03-05 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
US9849087B2 (en) | 2011-11-08 | 2017-12-26 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
US20130195963A1 (en) * | 2011-12-07 | 2013-08-01 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
US8926994B2 (en) * | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
US20210059942A1 (en) * | 2012-06-12 | 2021-03-04 | The Methodist Hospital Research Institute | Compositions and methods of treating therapy resistant cancer and uses thereof |
US20140010879A1 (en) * | 2012-06-12 | 2014-01-09 | The Methodist Hospital Research Institute | Compositions and methods of treating therapy resistant cancer and uses thereof |
US10842749B2 (en) * | 2012-06-12 | 2020-11-24 | The Methodist Hospital Research Institute | Compositions and methods of treating therapy resistant cancer and uses thereof |
WO2014036019A2 (fr) * | 2012-08-27 | 2014-03-06 | Red Lion Chem Tech, Llc | Procédés et compositions pour l'élimination des métaux lourds et pour administrer des agents souhaitables par voie orale |
US8883216B2 (en) | 2012-08-27 | 2014-11-11 | Red Lion Chem Tech, Llc | Methods and ceramic nanoparticle compositions for heavy metal removal and for oral delivery of desirable agents |
WO2014036019A3 (fr) * | 2012-08-27 | 2014-04-17 | Red Lion Chem Tech, Llc | Procédés et compositions pour l'élimination des métaux lourds et pour administrer des agents souhaitables par voie orale |
US20210205456A1 (en) * | 2012-09-19 | 2021-07-08 | Georgetown University | Targeted liposomes |
US11951167B2 (en) * | 2012-09-19 | 2024-04-09 | Georgetown University | Targeted liposomes |
US20170136123A1 (en) * | 2013-01-10 | 2017-05-18 | Amrita Vishwa Vidyapeetham | Stannous doped micro and nano particles for augmented radiofrequency ablation |
US20140356441A1 (en) * | 2013-05-31 | 2014-12-04 | Ricoh Company, Ltd. | Core-shell type particles and method for producing the same |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10837018B2 (en) | 2013-07-25 | 2020-11-17 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
US20160279187A1 (en) * | 2013-10-31 | 2016-09-29 | University Of Hawaii | Calpain inhibitors for ibd and colorectal cancer treatment |
WO2015066212A3 (fr) * | 2013-10-31 | 2015-12-30 | University Of Hawaii | Inhibiteurs de la calpaïne destinés au traitement de la maladie inflammatoire chronique de l'intestin et du cancer colorectal |
US10182988B2 (en) | 2013-12-03 | 2019-01-22 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US11883535B2 (en) | 2013-12-03 | 2024-01-30 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US10792251B2 (en) | 2013-12-03 | 2020-10-06 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US10495644B2 (en) | 2014-04-01 | 2019-12-03 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
WO2015176025A1 (fr) | 2014-05-15 | 2015-11-19 | The Methodist Hospital | Nanoconstructions polymères discoïdes et méthodes d'utilisation dans la théranostique du cancer |
US10995267B2 (en) | 2014-05-29 | 2021-05-04 | Crystalplex Corporation | Dispersion system for quantum dots having organic coatings comprising free polar and non-polar groups |
US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US11123294B2 (en) | 2014-06-04 | 2021-09-21 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US11957788B2 (en) | 2014-06-04 | 2024-04-16 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US10112198B2 (en) | 2014-08-26 | 2018-10-30 | Academia Sinica | Collector architecture layout design |
US10208310B2 (en) | 2014-10-06 | 2019-02-19 | Exicure, Inc. | Anti-TNF compounds |
US10760080B2 (en) | 2014-10-06 | 2020-09-01 | Exicure, Inc. | Anti-TNF compounds |
US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
US10736845B2 (en) | 2015-03-03 | 2020-08-11 | Cureport Inc. | Dual loaded liposomal pharmaceutical formulations |
US10561611B2 (en) | 2015-03-03 | 2020-02-18 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
US20170056327A1 (en) * | 2015-08-25 | 2017-03-02 | The Methodist Hospital | Micro/nano composite drug delivery formulations and uses thereof |
US12115229B2 (en) | 2015-12-21 | 2024-10-15 | Fidia Farmaceutici S.P.A. | Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes |
US11510995B2 (en) * | 2015-12-21 | 2022-11-29 | Fidia Farmaceutici S.P.A. | Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
US10605708B2 (en) | 2016-03-16 | 2020-03-31 | Cellmax, Ltd | Collection of suspended cells using a transferable membrane |
US11866700B2 (en) | 2016-05-06 | 2024-01-09 | Exicure Operating Company | Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA |
US11859118B2 (en) | 2016-05-19 | 2024-01-02 | Tectus Corporation | Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3D structure containing them and methods of making and using them |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11690920B2 (en) | 2017-07-13 | 2023-07-04 | Northwestern University | General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
WO2019157319A1 (fr) * | 2018-02-12 | 2019-08-15 | Flagship Pioneering Innovations V, Inc. | Dispositifs et procédés pour administrer une matière dans un tissu biologique ou une cellule |
US12116518B2 (en) | 2023-10-27 | 2024-10-15 | Tectus Corporation | Cadmium-free quantum dots, tunable quantum dots, quantum dot containing polymer, articles, films, and 3D structure containing them and methods of making and using them |
Also Published As
Publication number | Publication date |
---|---|
WO2008021908A2 (fr) | 2008-02-21 |
US20210338593A1 (en) | 2021-11-04 |
AU2007286203B2 (en) | 2013-05-02 |
US20160051481A1 (en) | 2016-02-25 |
JP2010500375A (ja) | 2010-01-07 |
US10143658B2 (en) | 2018-12-04 |
AU2007286203A1 (en) | 2008-02-21 |
MX2009001461A (es) | 2009-07-02 |
HK1140139A1 (en) | 2010-10-08 |
AU2007286203A2 (en) | 2009-03-19 |
US20190111000A1 (en) | 2019-04-18 |
EP2056794A2 (fr) | 2009-05-13 |
CA2664919A1 (fr) | 2008-02-21 |
CN101652126B (zh) | 2013-07-17 |
CN101652126A (zh) | 2010-02-17 |
EP2056794A4 (fr) | 2012-12-26 |
WO2008021908A3 (fr) | 2008-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210338593A1 (en) | Multistage delivery of active agents | |
Li et al. | Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy | |
Ashfaq et al. | Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment | |
Bisso et al. | Nanopharmaceuticals: A focus on their clinical translatability | |
A Santos et al. | Multifunctional porous silicon for therapeutic drug delivery and imaging | |
Athar et al. | Therapeutic nanoparticles: State-of-the-art of nanomedicine | |
Bazylińska et al. | Nanoemulsion-templated multilayer nanocapsules for cyanine-type photosensitizer delivery to human breast carcinoma cells | |
Vauthier | A journey through the emergence of nanomedicines with poly (alkylcyanoacrylate) based nanoparticles | |
Lv et al. | Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling | |
ES2951598T3 (es) | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos | |
JP2016531142A (ja) | ナノ構造送達系を使用する細胞特異的ターゲティング | |
Son et al. | Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration | |
Saharkhiz et al. | A new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast cancer | |
Carissimi et al. | Nanoparticles as drug delivery systems | |
Chen et al. | A dual-targeting nanocarrier based on modified chitosan micelles for tumor imaging and therapy | |
Ghazal et al. | Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment | |
Ahmad et al. | Applications of nanotechnology in pharmaceutical development | |
Hnawate et al. | Nanoparticle-novel drug delivery system: A Review | |
TWI472341B (zh) | 寡聚物奈米顆粒複合體釋放系統 | |
TWI483747B (zh) | 口服式藥物載體及其製備方法 | |
Ferrari et al. | Multistage delivery of active agents | |
KR20130088081A (ko) | 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법 | |
Barbosa et al. | Nanotechnology applied in drug delivery | |
Patel et al. | Design and development of glutathione conjugated poly (d, l) lactide nanocarriers for delivery of hydrophilic fluorescent marker across blood brain barrier | |
Thorat et al. | Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, OHI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FERRARI, MAURO;TASCIOTTI, ENNIO;SAKAMOTO, JASON;REEL/FRAME:020377/0154 Effective date: 20070918 Owner name: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FERRARI, MAURO;TASCIOTTI, ENNIO;SAKAMOTO, JASON;REEL/FRAME:020377/0154 Effective date: 20070918 |
|
AS | Assignment |
Owner name: US GOVERNMENT - SECRETARY FOR THE ARMY, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER HOUSTON;REEL/FRAME:020849/0735 Effective date: 20080116 |
|
AS | Assignment |
Owner name: NASA, DISTRICT OF COLUMBIA Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TEXAS HEALTH SCIENCE CENTER AT HOUSTON, UNIVERSITY OF;REEL/FRAME:022576/0736 Effective date: 20090204 Owner name: NASA, DISTRICT OF COLUMBIA Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON;REEL/FRAME:022576/0748 Effective date: 20090204 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |